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Breast cancer is a heterogeneous disease with vastly different tumor progression kinetics 
and survival outcomes depending upon the differentiation state and gene expression 
patterns of the tumor.  Effective treatments exist for patients with endocrine therapy 
sensitive or HER2 overexpressing tumors, but targeted treatments are not available for 
other tumor types. The mechanisms governing mammary tumor phenotype generation 
could prove critical to finding treatments.  The c-Jun N-terminal kinase (JNK) pathway 
has recently been implicated in the inhibition of breast tumor luminal differentiation (1, 
2) and JNK2, in particular, is important in mammary tumorigenesis and tumor 
progression (3-8).  Therefore, the involvement of JNK2 in inhibition of mammary 
luminal cell differentiation was investigated in normal glands and tumors.  Studies found 
that JNK2 inhibits luminal cell populations in normal mammary ducts. Additionally, 
JNK2 suppresses Notch activity in stem cell niche of the developing mammary gland.  In 
vitro assays show that control over differentiation by JNK2 is due to suppression of p53-
dependent Notch1 expression.  Inhibition of luminal cell populations by JNK2 is also 
 vii 
apparent in tumor cell models regardless of p53 expression.  In the p53-competent 
Polyoma Middle T-antigen model, Notch1 expression is suppressed by JNK2.  In the 
absence of p53, JNK2 suppresses luminal populations independent of Notch1.  In this 
model, decreased luminal marker expression is accompanied by increased epithelial to 
mesenchymal transition.  It was also found that JNK2-dependent epithelial to 
mesenchymal transition inhibits luminal populations and is driven by JNK2-dependent 
suppression of Brca1. JNK2 also confers resistance to estrogen signaling inhibition, and 
increases the metastatic ability of tumor cells in vivo.  These data establish the 
importance of JNK2 in mammary epithelial cell differentiation in normal glands and 
tumors.  They also suggest that JNK2 may be an effective prognostic marker or treatment 
target. 
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Chapter 1 – Introduction 
 
 
1.1. NORMAL MAMMARY DIFFERENTIATION 
 The mammary gland is the principle organ for the classification of mammals 
(Figure 1.1).  It has evolved for the nutrition of offspring that are essentially helpless at 
birth.  Human and mouse mammary glands carry out the same function and have 
remarkably similar structures.  The key difference is that female mice possess ten 
mammary glands while humans have only two (Figure 1.2).  This is presumably due to 
relative litter size.  Lactating mammary glands release nutrients to young, in the form of 
milk, from external orifices called nipples. These nipples lead to a network of 
interconnected, epithelial, tube-like ducts that lie in a large adipose fat pad stroma.  The 
functional portion of the gland is the duct, which undergoes periodic changes under the 
influence of sex hormones to prepare for potential pregnancy.  Human mammary glands 
also possess a structure called the lobule that is present at all times and is the site of 
differentiation into milk-producing alveolar units during pregnancy. 
 Mammary ducts are bi-layered, ovular structures.  Ductal layers are segregated 
into two distinct lineages that have similar gene expression patterns and functions in mice 
and humans (Figure 1.3).  The inner layer confines cells of the luminal lineage and the 
outer layer consists of the basal/myoepithelial lineage.  As the names suggest, luminal 
cells are directly associated with the hollow lumen while basal cells are in direct contact 
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with the basal lamina. Each cell type has its own specific function in the mammary gland.  
Cells of the luminal lineage are able to differentiate into secretory cells of the alveolar 
buds and produce milk proteins, while basal/myoepithelial cells provide the physical 
force necessary to expel milk through ducts toward the nipple.  The basal compartment is 
less differentiated and contains stem cells, which give rise to cells of both lineages (9-11).   
Luminal and basal lineages of the mammary gland can be distinguished from each 
other by their expression of immunohistochemical or flow cytometric markers.  The 
markers for mammary lineages are quite similar for mice and humans.  For reference, cell 
type markers can be found on Table 1.1.  By immunohistochemistry, luminal cells can be 
discriminated from basal cells by their expression Cytokeratins 8 and 18, MUC1, ER, and 
PR, while basal cells express Cytokeratin 14, smooth muscle actin, and p63 (12).  By 
flow cytometry, mammary lineages can be easily separated on the basis of Heat Stable 
Antigen (CD24) and either Integrin α6 (CD49f), or Integrin β1 (CD29) expression (10, 
11, 13-16).  Luminal lineages are CD24
hi
 CD49f
lo/med
 CD29
hi
 and basal/myoepithelial cell 
lineages are CD24
lo 
CD49f
hi
 CD29
hi
.  Mammary stem cell populations possess an 
expression signature similar to the highest CD49f/CD29 expressing basal cells (9-11).  It 
is important to note that the same markers that discriminate lineages in the normal 
mammary gland also define tumors that arise from a particular lineage. 
In the mammary epithelial cell hierarchy, mammary stem cells divide and 
daughter cells either retain stem cell characteristics, through symmetric divisions, or 
divide asymmetrically generating a single stem cell and a daughter cell that is committed 
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to differentiation (Figure 1.4). One key protein that promotes mammary stem cell 
maintenance is Bmi-1 (17).  Expression of Bmi-1 in stem cells is promoted by the process 
of epithelial to mesenchymal transition (EMT) (18, 19), which is, itself, a defining 
characteristic of adult stem cells (20).  Stem cell maintenance is inhibited by p53 in a 
poorly understood mechanism, which involves inhibition of symmetric cell divisions 
(21).  This mechanism may involve p53-dependent transcription of miR200c, as this 
function suppresses EMT and stem cell characteristics in mammary cells (22).  Once 
stem cells asymmetrically divide, a bipotent progenitor is generated with the potential to 
maintain basal fate or adopt a luminal one (23).  
Notch signaling is important for commitment of cells to the luminal lineage and 
inhibition of commitment to the basal lineage (24-26).  Notch signaling does not promote 
terminal differentiation of luminal cells, however, as overexpression of Notch1 results in 
build-up of luminal progenitor cells (24, 25, 27).  Although Notch1-3 are all expressed in 
the developing and adult mammary gland, Notch1 mRNA is expressed the most 
differentially between luminal and basal lineages, with highest expression in luminal 
cells, and is considered the most important for mammary cell differentiation (25). A key 
function of Notch1 in luminal cell differentiation is suppression of Trp63 (the gene 
encoding p63) transcription, which itself inhibits Notch1 transcription and promotes basal 
lineage commitment (28-30). 
Terminal differentiation along the luminal lineage depends upon the GATA3 
transcription factor and Breast Cancer-associated-1 (BRCA1).  Expression of both genes 
is stratified by cell populations, with highest expression in luminal progenitor cells (31-
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33).  This compartmentalization serves a functional role in allowing them to drive 
differentiation of luminal progenitors into mature, ER
+
 luminal cells (33-35).  In the 
absence of expression of either gene, luminal progenitor cells predominate the mammary 
ductal architecture. 
1.2.BREAST CANCER DIFFERENTIATION 
 
Despite the relatively simple structure of the mammary gland, with only two cell 
lineages, breast cancer is a remarkably heterogeneous disease.  Historically, human breast 
tumors have been categorized by expression of three biomarkers in histology: ER, PR, 
and HER2 (36).  The expression level of each marker has been used to determine 
treatment regimens for chemo- radiation- and endocrine therapies.  While this approach 
has been successful in treatment of localized disease, patients with metastatic breast 
cancer only see 5-year survival rates of 27% (37).  This demonstrates a need for better 
understanding of breast cancer development and gene expression.  
Many other immunohistochemical biomarkers have been proposed as 
prognostic/predictive indicators of treatment outcome, but the heterogeneity of breast 
cancer has necessitated a transcriptome-wide approach to classification.  Microarray-
based methods have yielded several distinct subtypes with unique tumor characteristics 
and predictive patient outcomes (38-40).  The most widely accepted subtypes of human 
breast tumors are luminal A, luminal B, basal-like, and HER2
+ 
(HER2-overexpressing), 
each named according to similarity with normal mammary lineages.  A very important 
feature of these subtypes is that primary tumors and metastases from those tumors 
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possess similar gene expression patterns, a fact that suggests subtype-specific treatments 
may target both sites (38). 
Just like the normal luminal lineage, luminal subtypes express high levels of ER, 
ER-target genes, luminal Cytokeratins, and luminal transcription factors such as Gata-3. 
By contrast, basal-like and HER2
+
 tumors are characterized by their low or absent 
expression of ER and its associated transcripts (39).  Luminal tumors are by far the most 
common subtypes and they are the most differentiated breast tumors (41).  Luminal A 
and B differ in that Luminal A tumors proliferate and progress more slowly (41, 42).  
Luminal A tumors are effectively treated with endocrine therapy, whereas luminal B 
tumors are not responsive (43).  Basal tumors progress quickly and express high levels of 
proliferation-related genes, EMT markers, and basal Cytokeratins (41, 44-46).  There is 
no effective, targeted therapy currently available to patients with basal tumors.  HER2 
over-expressing tumors are also highly proliferative and progress quickly to metastasis 
(47). However, this phenotype is well-known to be dependent on the HER2 receptor—a 
fact that is effectively exploited by treatment of patients with the transtuzumab 
(Herceptin
TM
) monoclonal antibody (48-52).   
Recently, another group of tumors has been discovered with characteristics of 
cancer stem cells, called claudin-low.  This group has been described as an “emerging” 
subtype and is named for it’s low expression of Claudins 7 and -9, as compared to other 
tumor subtypes (41).  Claudin-low tumors have histology characteristic of cells 
undergoing EMT (53).  As evidence for enrichment in cancer stem cells, claudin-low 
tumors also express the highest levels of tumor initiating cell-related genes among all 
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tumor subtypes (41).   Claudin-low tumors are also the least differentiated subtype, with 
basal, HER2, and Luminal tumors following in increasing order (33, 41). 
Each subtype is hypothesiszed to be generated from aberrant expression of 
charcteristic gene products (41).  Few mechanisms of subtype generation, however, are 
known.  One that is well-studied is the mechanism of HER2+ subtype generation, which 
results from a relatively common, spontaneous, gene amplification at the erbb2 (the gene 
encoding HER2) locus (54).  Basal tumors are not generated from a single specific 
mutation, as in HER2 tumors, but several potential genes that are involved in mammary 
cell differentiation.  For example, inherited mutations in Brca1 pre-dispose individuals to 
the development of basal-like breast cancers (55-57).  Tumors in Brca1 mutation carriers 
are generated from a build-up of luminal progenitor cells, not basal cells as the subtype 
name would suggest (33).  This is, presumably, due to the active role of BRCA1 in 
terminal differentiation.  Similarly, high expression of Notch1, which is involved in 
production of luminal progenitors, results in the generation of basal tumors in mice and 
humans (25, 27, 58, 59).   
The generation of luminal and other tumor subtypes is more speculative.  For 
example, GATA-3 is a master regulator of luminal cell fate and it is also one of the core 
genes that define luminal tumors.  Thus, it is believed that GATA-3 may also be 
necessary for generation of luminal subtype or ER
+
 tumors (60).  However, additional 
studies must be done to better define the role of GATA-3 in luminal tumorigenesis.   
EMT is an important factor in maintenance of stem cell populations and as a defining 
characteristic of the claudin-low subtype of tumors may very well be a determinant in 
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their generation (33, 60).  This is a question of great importance because cancer stem cell 
populations are hypothesized to be responsible for tumor generation and information 
regarding claudin-low tumors may provide insight for all tumor subtypes. 
Although some of the important molecules and effectors that are involved in 
subtype generation are known, many remain to be discovered and the upstream elements 
that mediate subtype generation are even less well-described.  Knowledge of these 
upstream effectors could prove useful in the design of targeted therapies for treating 
patients with metastatic disease. 
1.3.  C-JUN N-TERMINAL KINASES (JNKS) 
 
One potential upstream regulator of mammary cell differentiation and tumor 
subtype generation is the C-Jun N-Terminal Kinase (JNK) pathway.  There is evidence 
that the JNK pathway inhibits commitment luminal populations in breast cancer.  Recent 
studies show that inactivating mutations in the upstream JNK activating kinases 
MAP3K1, MAP2K4, and MAP3K13 are prevalent in luminal breast tumors, occurring 
most frequently in ER
+
 tumors (1, 2).  Because JNKs are effectors of this pathway, these 
data may indicate a role for them in normal mammary lineage commitment also.  
Activation of JNKs has been reported in response to a wide variety of signaling 
pathways and ligands including EGF (61), canonical and non-canonical Wnt signaling 
(62-64), FGF (65), TGFβ (66-68), TNFα (69-71), and integrins (72).  These signals 
induce phosphorylation of JNKs, triggering their subsequent activation of nuclear and 
cytoplasmic substrates, including c-Jun.  JNKs have been shown to possess near 
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ubiquitous cellular functions including apoptosis (66, 67, 73-79), cell cycle progression 
(71, 80-88), differentiation (64, 89-92), EMT (85, 93-96), and others.   
There are three JNK genes encoding JNKs 1-3, which alternatively splice into 
several isoforms.  Expression of Jnk1 and Jnk2 is widely recognized to encompass all 
tissues whereas Jnk3 is thought to have a more limited expression pattern, mostly in the 
brain, heart and testis (97).  JNKs are proline-directed serine/threonine mitogen-activated 
protein kinases (MAPKs) that phosphorylate substrates at (Pro)-X-Ser/Thr-Pro sequences 
(98)—a similar motif to the substrate of other members of the MAPK family, including 
ERK (99).  Structures of each of the JNK proteins contain binding sites for ATP, an 
activation loop, and a MAPK insert domain (100-102).  JNKs are phosphorylated on their 
respective activation loops, which require dual phosphorylation of a tyrosine and a 
threonine to potentiate functionality.  Phosphorylation is catalyzed by MAPK kinase 
(MAP2K) 4 and -7 and although both kinases have dual specificity (ability to 
phosphorylate Ser/Thr or Tyr), MAP2K4 preferentially interacts with tyrosine residues 
and MAP2K7 interacts with threonine residues of JNKs (103).  
Although JNKs do possess overlapping function, recent studies in JNK knockout 
mouse models and other specific gene targeting strategies have demonstrated that JNK 
proteins also possess individual, unique, substrates and cellular activities.  Activator 
Protein 1 (AP-1) transcription factor complex proteins, including c-Jun, are bound and 
phosphorylated by JNK family members with varied affinity (104-106).  JNK2 has the 
highest affinity for c-Jun and ATF2, while JNK3 binds to Elk-1 with the greatest 
efficiency.  (106).  JNK1 and JNK3 isoforms preferentially bind to c-Jun, but the affinity 
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of JNK2 is dependent upon isoform.  JNK2α1 and -α2 preferentially bind to c-Jun while 
JNK2β1 and –β2 preferentially bind to ATF2.  These studies and others have defined 
characteristic functions of each individual JNK gene.  Whereas JNK1 is associated with 
promotion of apoptosis, JNK2 promotes the converse process of cell survival (81).  JNK3 
is primarily involved in apoptosis in neural tissues (76, 107). 
 The roles of individual JNK genes in mammary biology are not well understood.   
Although Jnk1 and Jnk2 do not seem to affect adult mammary morphology in vivo, 
double-null mammary cells display an increased branching phenotype in culture (4, 5).  
Additionally, inhibition of JNKs prevents AP1- and Bim-dependent acinar apoptosis and 
lumen clearing in 3-dimensional mammary epithelial cell cultures (108).  While these 
studies support a role for JNKs in mammary biology, their methods prevent assignment 
of individual JNK gene function—further research in this area is warranted.  Given that 
JNK isoforms perform unique functions, it is probable that the ubiquitously expressed 
Jnk1 and Jnk2 affect mammary development in different ways. 
1.4.DISSERTATION AIMS 
Breast cancer is the most commonly diagnosed cancer in women of the United 
States (109). Early detection methods have improved overall survival, but the dismal 
survivorship for metastatic disease only serves to illustrate that deeper understanding is 
required to design reliable treatment regimens for all that are affected with breast cancer.  
The most effective treatments may be rationally designed by analyzing molecules and 
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cellular signaling pathways that are important for the development and progression of the 
disease. 
 Recent publications have shown that C-Jun N-terminal Kinase 2 (JNK2) is 
responsible for a range of processes in the mammary gland from normal development to 
tumorigenesis and tumor progression.  The Van Den Berg lab and others have shown 
that, in breast cancer models, JNK2 promotes accumulation of replicative stress (3), 
tumorigenesis (4), cell motility (6, 7), and metastasis (8).  These activities may be due to 
the promotion of EMT by JNKs (93).  If this is so, the necessity for EMT in development 
and differentiation, points to a potential role of JNK2 in these processes, as well.  This is 
further supported by the potential for the JNK pathway to inhibit differentiation along the 
luminal lineage in breast tumors (1, 2).  These data led to development of the hypothesis 
that JNK2 inhibits luminal lineage commitment in mammary tumors.  Because 
mechanisms governing differentiation in mammary tumors are related to those in the 
normal mammary gland, it was also hypothesized that JNK2 inhibits luminal lineage 
commitment in the normal mammary gland. 
 The studies documented herein address the role of JNK2 in mammary gland 
development and differentiation in normal and tumor tissues.  They provide unique 
insight into the importance of mammary epithelial cell differentiation in tumor phenotype 
as tested through the following experimental aims: 
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Aim 1:  Determine the specific alterations in luminal cell marker or lineage-specific 
gene expression that result from null mutation of Jnk2 (jnk2ko) in normal mammary 
glands and tumors. 
Aim 2:  Define the mechanisms of luminal cell commitment that are altered by 
jnk2ko. 
Aim 3:  Establish a connection between alterations of luminal cell commitment to 
mechanisms of commitment that are altered by jnk2ko. 
 
 These aims were tested by the methods presented in Chapter 2.  Data gained 
through experimentation is presented and discussed in Chapters 3, 4, and 5. A summary 
of results and future directions is included in Chapter 6. 
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Chapter 2 – Materials and Methods 
 
 
 
Mice 
All mouse experiments were performed in accordance with institutional and national 
guidelines and regulations. Animal procedures and experiment are pre-approved by the 
IACUC at the University of Texas, Austin.  Trp53-null (p53ko) (110) and jnk2ko (111) 
mice were obtained from Jackson Labs and backcrossed to Balb/C strain (Jackson Labs). 
Reagents  
Unless otherwise stated, chemical reagents were purchased from Sigma. Antibodies used: 
1:500 CK8/18 (Santa Cruz Biotechnology, Inc. #sc-52325), 1:500 p63 (Millipore 
#MAB4135), 1:500 Ki67 (Neomarkers, Fischer Scientific #RM-9106), 1:500 Cleaved 
Caspase-3 (Cell Signaling #9664) 1:500 SMA (DakoCytomation #M0851), 1:500 Notch1 
(Millipore #491010), 1:500 Notch1
ICD
 (Cell Signaling #2421), 0.5uL/0.5M cells CD24-
PECy7 (Ebioscience #25-0242), 0.5uL/0.5M cells CD49f-PE (Ebioscience #12-0495), 
1:500 Six1 (Origene #TA504057), 1:500 MMP9 (Cell Signaling #3852), 1:500 E-
cadherin (Cell Signaling #3195), 1:500 Vimentin (Cell Signaling #3932), 1:500 Lef-1 
(Cell Signaling #2230), 1:500 ER (Santa Cruz #sc-542), 1:500 PR (Santa Cruz #sc-539), 
1:1000 GAPDH (Cell Signaling #2118), 1:500 Zeb1 (Cell Signaling #3396), Mouse 
HRP-conjugated secondary antibody (Santa Cruz #sc-2031), Rabbit HRP-conjugated 
secondary antibody (Santa Cruz #sc-2030), 1:500 Mouse lineage panel kit including 
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CD3e, CD11b, CD45R, Ly6G & C, Terr-119 used per manufacturer’s instructions (BD 
Pharmingen #559971). BrdU-FITC kit was used per manufacturer’s instructions, as 
explained below (BD Pharmingen #559619).  Adenoviral MAM51 was a kind gift from 
Karine LeFort and G. Paolo Dotto (112).  Notch1 promoter constructs were a kind gift 
from Takashi Yugawa (113).  BRCA1 promoter constructs were a kind gift from David 
Rodenhiser (114). 
Tissue processing and histology 
Number four glands from five 3-, 4-, 5-, 6-, and 7 week-old virgin female mice were 
fixed with 4% paraformaldehyde and paraffin (Fisher Scientific # 23-021-401) embedded 
using a Leica TP1020 Tissue Processor and a Leica EG1150H/C Tissue Embedding 
Station. Eight unique tumors were used for each assay in tumor models.  5um sections 
were cut using a Leica RM2255 Microtome and placed onto slides.  Tissue was treated 
with Citrisolv (Fisher Scientific #670209), rehydrated and boiled in 10mM Na Citrate. 
Tissue was permeabilized with 0.02% Triton X-100.  Immunohistochemistry samples 
were treated with 0.3% H2O2 before incubation with primary antibodies and then treated 
according to ABC kit (Vector Labs, Mouse-#AK-5002, Rabbit #AK-5001) instructions.  
Samples were developed with the DAB substrate kit (Abcam #ab64238) and then 
mounted with VectaMount (Vector Labs #H-5000). Immunofluorescence samples were 
incubated with primary antibodies at concentrations listed above, overnight at 4 C.  
Samples were then washed with PBS (137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, 
1.8mM KH2PO4) and incubated with fluorescently-labeled secondary antibodies at room 
temperature for one hour, washed again, and mounted with VectaShield with DAPI 
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(Vector Labs #H-1200). Immunohistochemistry images were obtained using an Olympus 
CKX41 bright-field microscope with QCapture Pro software (Media Cybernetics). 
Immunofluorescence images were obtained on an Eclipse TE200 microscope (Nikon) 
using Image Pro Plus Software.  Photographs were taken of 10 60X fields 
(immunofluorescence) or 10-40X fields (immunohistochemistry) from each gland/tumor 
involved in the study. 
Western blot 
Cell pellets were lysed in Protein Extraction Buffer (20mM Tris pH 7.6, 50mM NaCl, 
3mM EDTA, 0.05% NP-40 in dH2O) or RIPA buffer (50mM Tris p  7.4, 1  m  NaCl, 
1m   DTA,  .1   D , 1  N -4 ,  .    odium Deoxycholate) with protease inhibitor 
cocktail ( ug m   eupeptin, 1m  DTT, 1m     F, 1  Aprotinin,  6 ug m  Na-
 rthovanadate).   amples were fro en at -2  C and thawed on ice to allow lysis.  
Following lysis, samples were centrifuged in a micrcentrifuge at full speed for 1  minutes 
at 4 C.  Concentrations were calculated based off of a B A standard curve, using DC 
Protein Assay System (Bio-Rad #500-0111).  Protein samples were prepared in 4X SDS 
loading buffer (40% glycerol, 50mM Tris pH 6.8, 8% SDS, 0.4% Bromophenol blue).  
Gels were cast at 8-12% polyacrylamide, using the Protean III system (Bio-Rad).  Gels 
were run at 200V in Tris-Glycine (25mM Tris, 0.2M Glycine, 0.1% SDS, pH 8.3) and 
then transferred to 0.2um pore nitrocellulose (Bio-Rad #162-0112) in Tris-Glycine with 
20% Methanol.  Blots were then blocked with 4% powdered milk in TBS-T (50mM Tris, 
150mM NaCl, 0.05% Tween-20, pH 7.6), washed in 1X TBS-T and then probed with 
primary antibodies overnight at 4 C.  After washing with three times in TB -T, blots were 
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incubated with HRP-conjugated secondary antibodies for 1 hour at room temperature.  
Blots were developed using ECL-Plus Reagent (Amersham #PRPN2132) on a STORM 
860 Molecular Imager (Amersham). 
Primary Mammary Epithelial Cell Culture and Imaging 
Mammary Glands from three adult (8-10 week-old) virgin female mice were extracted 
and minced and treated with 5 mg/mL collagenase for 1.  hours at  7 C with rocking, 
until well-digested. Mammary organoids were isolated by four rounds of differential 
centrifugation at 500xg for 30 seconds.  Organoids were disaggregated with 0.025% 
trypsin/EDTA (Invitrogen #R-001-100). Cells were filtered through 40um cell strainers 
(Fisher Scientific #08-771-1).  3-dimensional cultures were seeded on Matrigel (BD 
Biosciences #356234) according to established protocols (115, 116). 50 Acinar diameters 
for each treatment were measured at 24-hour intervals from bright field images with 
QCapture Pro Software. Immunofluorescence images were obtained using an SP2 AOBS 
Confocal Microscope (Leica) from a minimum of 15 acini per treatment.  Differentiation 
assays were performed on isolated mammary epithelial cells after sorting for colony 
forming units (CD24
hi
 CD49f
lo
) or mammary repopulating units (CD24
lo
 CD49f
hi
) with 
flow cytometer.  4000 mammary epithelial cells were then plated in 60mm dishes in 
triplicate with 4 ,    NI  T  cells that had previously been cell cycle arrested by γ-
irradiation at 50 Gy.  Cells were plated in Epicult B Medium (Stem Cell Technologies 
#  61 ) according to the manufacturer’s protocol.  After eleven days, cell media was 
removed and cells were fixed in 4% paraformaldehyde, washed with 1X PBS, then cells 
were stained with Geimsa and cells were imaged by brightfield microscopy as above. 
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qPCR 
RNA was isolated from cells or tissue as described in text using Trizol Reagent 
(Invitrogen #15596). Primers were designed using PerlPrimer with at least one primer of 
each pair spanning an intron. RNA was reverse-transcribed using MMLV High 
Performance Reverse Transcriptase (Epicentre #RT80110K).  0.005ug of cDNA for each 
well, in triplicate, was amplified using specific primers and SYBR Green SuperMix-
UDG (Invitrogen 11733-038) at 1/8X concentration in 96-well plates. Fluorescence was 
measured in a Stratagene Mx3005p qPCR Thermal Cycler (Agilent Technologies). 
Relative expression was calculated against standard curves with glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) as normalizer, using MxPro Software (Agilent 
Technologies). All primers can be found in Appendix D.  Normal mammary assays 
examined organoid preparations from three glands of each genotype.  Tumor assays 
examined RNA from eight tumors of each genotype. 
Flow Cytometry 
Single cell suspensions were isolated from mammary glands as above or from culture and 
incubated with fluorescently tagged antibodies, listed in reagents.  Antibody incubations 
were carried out on single cell suspensions for one hour at 4 C in cell staining buffer (2  
Bovine Serum Albumin, 2mM EDTA, in 1X PBS). Cells were then washed in cell 
staining buffer, centrifuged at 300xg for 5 minutes and resuspended in cell staining 
buffer.  Labeled experimental cells, unlabeled control, and singly labeled compensation 
controls were then run in triplicate on Millipore Guava Easy Cyte 8HT or BD 
Biosciences FACSAria II and analyzed using FloJo 9.3.1 software (Treestar Inc).  For 
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normal mammary assays, lineage panel-negative cells were gated to analyze CD24 and 
CD49f populations.  For BrdU assay, cells were gated against CD24 to analyze CD24
+
 
and CD24
-
 populations. 
p53ko Mammary Gland Transplants 
Mammary glands from sexually mature p53ko;jnk2wt or p53ko;jnk2ko female (five of 
each genotype) mice were transplanted as 5mm
2
 pieces into cleared fat pads of 25 3 
week-old wildtype females per genotype, with an average of five transplants per donor. 
Transplant surgeries were carried out under anesthesia with 500uL of 0.2% Avertin 
Tribromoethanol solution for recipients and 750uL for donors.  Two weeks after 
transplantation, pituitary glands were extracted from sexually mature female mice (one 
whole pituitary gland per mammary transplant recipient) and placed within the kidney 
capsule of each mammary transplant recipient, under anesthesia, as described (117). 
Mammary transplants were palpated three times weekly until tumors were palpated and 
tumors were measured with caliper until they reached a target size of 1.5cm diameter.  
Tumors were then harvested and cut into pieces and flash frozen for RNA, fixed in 4% 
paraformaldehyde for histology, or minced for cell line generation. 
Cell lines  
MT
+
jnk2ko cell lines were previously generated from MT tumors and GFP and GFP-
JNK2 genes were stably integrated (3). Cell lines from p53ko tumors were generated 
after harvest from transplant recipient mice at target size. Whole tumors were minced and 
treated with 5 mg/mL collagenase, then rocked at  7 C for four hours or until suitably 
digested—prior to single cell suspension. Tumor organoids were then enriched by four 
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rounds of differential centrifugation at 500xg with PBS washes. Cells were plated in eight 
10cm diameter dishes in DMEM/F12 with 1% FBS.  Cells were treated with 2.5mg/mL 
Dispase to remove fibroblasts and cultures were combined after crisis to generate 
immortalized cell lines.  MT cells and p53ko cells were maintained in DMEM/F12 
medium (Mediatech Inc.#10-090) supplemented with 10% Benchmark FBS (Gemini 
#100-106), 1 μg ml  umulin® R U-100 (Lilly #0002-8215-01), 5ng/ml EGF (Peprotech 
AF-100-15), penicillin/streptomycin (Life Technologies #15070-063). GFP and GFP-
JNK2 constructs were stably expressed p53ko cells by using the GP2-293 cell retroviral 
packaging system (Clontech).  GP2-293 cells were plated on 10cm dishes at a density of 
800,000 cells.  After attaching, cells were transfected with 10ug total DNA (5ug construct 
plus 5ug VSV-G) using 20 uL of Lipofectamine 2000 Reagent (Life Technologies 
#11668) in DMEM without serum or antibiotics.  Media was replaced, after four hours of 
incubation, with target cell media and viral media was placed onto target cells at 48 hours 
and 72 hours post-transfection.  Cells were selected with 5ug/mL Puromycin and 
populations were assessed for construct expression.   
Luciferase assay 
MT+jnk2ko GFP and GFP-JNK2 cells were plated at 400,000 cells per 10cm dish and 
allowed to attach overnight.  Cells were transfected with 5ug total DNA of both 
luciferase constructs and CMV-Beta-galactosidase or CMV-Luciferase as positive 
control, using 10uL Lipofectamine 2000 Reagent. Cells were harvested using Reporter 
Lysis Buffer (Promega #E3971). Lysates, in quadruplicate, were exposed to Luciferase 
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Assay Reagent (Promega #E1483) or w-nitrophenyl-β-D-galactopyranoside (Fisher 
Scientific PI-34055) and read on a Synergy 4 Plate reader (BioTek). 
Chromatin Immunoprecipitation Assay 
20 million cells of each genotype, in 10cm cell culture dishes, were fixed at room 
temperature in 1% formaldehyde to facilitate cross-linking of protein-DNA complexes.  
Cross-linking reactions were stopped after 10 minutes with 125mM glycine (added 
directly to media) then cells were washed with ice cold 1X PBS three times before 
scraping into 1mL 1X PBS with protease inhibitor cocktail.  Cells were then centrifuged 
at 400xg for 5 minutes and supernate removed.  Cells were then lysed for 10min on ice in 
600uL 5mM Pipes (pH  . ),   m  KCl,  .   N -4  with protease inhibitor cocktail 
minus DTT.  Then cells were pelleted at      R   in microcentrifuge at 4 C.   upernate 
was removed and DC Protein Assay was performed on this liquid to normalize sample 
concentrations.  Then nuclei were lysed on ice in 200uL of 50mM Tris (pH 8.1), 10 mM 
EDTA, 1% SDS with protease inhibitor cocktail, while vortexing every 30 seconds at full 
speed for 10 minutes.  Then chromatin was sheared by bath sonication in an Episonic 
Bioprocessor (Epigentek), at Amplitude  6,   times for 2  seconds with 2  second rests 
on ice.   amples were then centrifuged in a microcentrifuge at 4 C and full speed for 1  
minutes.  Supernate containing chromatin fragments was removed diluted by adding 
450uL of 0.01% SDS, 1.1% Triton X-100, 1.2mM EDTA, 16.7mM Tris (pH 8.1), 167 
mM NaCl with protease inhibitor cocktail. Samples were divided approximately into 
thirds (~200uL) in microcentrifuge tubes. One tube was frozen for use as input and 30uL 
of 50% protein A sepharose beads (Fisher Scientific #26159) that had been pre-cleared 
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with sonicated salmon sperm DNA (Amresco 309-566-6) was then added to the sonicated 
chromatin samples along with either 1:500 anti-mouse p53 antibody (Cell Signaling 
#2524) or 1:50,000 IgG (Calbiochem NI  ) were added.   amples were then rocked on a 
rotary nutator overnight at 4 C.   amples were then centrifuged at     R   in 
centrifuged for one minute, then washed with the following solutions plus protease 
inhibitor cocktail: 0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris (pH 8.1), 
150mM NaCl, then 0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris (pH 8.1), 
500mM NaCl then 0.25M LiCl, 1% NP-40, 1% deoxycholate, 1mM EDTA, 10mM Tris 
(pH 8.1) then twice with 1X TE Buffer (10mM Trist pH 8.1, 1mM EDTA pH 8.0).  
Samples were then eluted from beads by adding 2  u  1   D ,  .1 Na C   and 
incubating samples at 6  C for 4  minutes, with shaking.   amples were flicked every 1  
minutes during this incubation to resuspend bead/chromatin complexes.  Next, samples 
were centrifuged at full speed in a microcentrifuge for   minutes at 4 C and supernate 
with liberated chromatin was moved to a fresh tube.  Input samples were then thawed and 
cross-links of all samples were reversed by addition of 1uL 20mg/mL RNase A (Life 
Technologies 12 91-  9), 17. u  of    NaCl, and incubation at 6  C for five hours with 
shaking.  7  u  of 1    ethanol was then added and samples were precipitated 
overnight at -2  C.  DNA was then centrifuged at full speed in a microcentrifuge and 
supernate removed.  The resulting pellets were resuspended in 100uL of dH2O, 2uL 
0.5M EDTA, 4uL 1M Tris (pH 6.5), and 1uL 20mg/mL Proteinase K (Fisher Scientific 
#BP1700).  Then samples were incubated for 2 hours at 4  C.  After digestion, DNA was 
isolated using a DNEasy kit (Qiagen #69  4) according to manufacturer’s instructions 
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with 50uL final elution volume.  2uL of final input samples and 15uL for 
immunoprecipitated samples were amplified by PCR using specific primers, listed in the 
appendix.  
Microarray Analysis 
Cell pellets were collected for p53ko cell lines and tumors (10 p53ko;jnk2ko and 4 
p53ko;jnk2wt), then lysed and processed using the RNEasy Kit (Qiagen #74104), to 
purify total RNA. RNA was sent to the Charles Perou Lab at the University of North 
Carolina at Chapel Hill, where probe labeling and hybridization was carried out by Adam 
Pfefferele, using Agilent custom 4X180K microarrays as previously described  (118). 
The microarray data was uploaded to the University of North Carolina Microarray 
Database (UMD)
 
(https://genome.unc.edu/pubsup/breastGEO/clinicalData.shtml) and to 
the Gene Expression Omnibus (GEO) under accession number GSE40226. Hierarchical 
clustering was performed using Gene Cluster 3.0
 
(119) and the data was viewed using 
Java Treeview version 1.1.5r2
  
(120). Statistically significant expression changes between 
tumor genotypes were determined using a 2-class unpaired significance analysis of 
microarray ( A ) analysis, with genes having a false discovery rate (FDR) ≤   
considered statistically significant.  
BrdU Assay 
600,000 cells were plated onto 10cm dishes then allowed to attach and recover for 23 
hours in full media (as described above).  Cells were then incubated with a 1mM BrdU 
solution (BD Biosciences BD Biosciences #550891) at a 1:100 dilution.  Cells were then 
harvested with trypsin-EDTA and quenched with full media, strained through a 40um 
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strainer, and then counted.  Live cells were next incubated with a CD24-PE-Cy7 antibody 
in cell staining buffer.  After washing, cells were incubated with 
fixation permeabili ation buffer (BD Biosciences #  4714) for    minutes at room 
temperature.  Cells were then washed with 1   B  and incubated with    ug m  in 1  
 B  for 1 hour at  7 C. Cells were then washed with 1   B  and resuspended in 1  
 erm ash Buffer (BD Biosciences #  472 ) and BrdU-FITC antibody and incubated 1 
hour at 4 C.   Cells were then washed with 1   B  and resuspended in cell staining buffer 
and plated in triplicate in a 96-well plate for analysis by flow cytometer. 
Limiting Dilution Tumor Assay 
Cell lines were trypsinized and recovered in full media counted, before passing through a 
40um cell strainer and counting.  Serial dilutions of 10,000, 1,000, and 100 cells per 50uL 
of sterile filtered normal saline (Biochemika #07982).  50uL of cells were then injected 
of cells into #2 mammary glands of nude mice using a Hamilton syringe (Hamilton 
Company #7638-01).  Tumors were palpated thrice weekly.  To determine tumor 
initiating cell frequency, L-Calc v1.1 (Stemsoft Software) was used. 
Statistics 
Statistical analyses were performed using  rism  oftware (Graph ad).  tudent’s T-test 
was employed to determine significance of single variable data. Significant data from T-
test is indicated on figures as follows:  * for  .  ≥p≥ . 1, ** for  . 1>p≥ .   1, *** for 
p<0.0001.  Significance for survival data was determined using Logrank test, where 
p<0.05 was considered significant.  2way ANOVA with Bonferroni Post-test was 
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employed to determine significance of multi-variable data.  Data was considered 
significant if p<0.05.  Error bars are shown as standard deviation.  
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Chapter 3 – JNK2 Inhibits Notch-Dependent Mammary Luminal Cell 
Differentiation 
 
 
 
3.1. JNK2 INHIBITS MAMMARY LUMINAL CELL DIFFERENTIATION IN VIVO 
 
To test if mammary cell differentiation is altered in the absence of JNK 
expression, seven week-old virgin mammary glands from Jnk2-null (jnk2ko)and wildtype 
(jnk2wt) female mice mammary glands were harvested, paraffin-embedded and examined 
for discrepancies in expression of myoepithelial (p63) and luminal markers (Cytokeratin 
8/18 and ER), p63 in histologic samples. This time point was used to ensure counting of 
only mature ducts in fully invaded fat pads of both genotypes. 
Analyses of lineage markers showed that jnk2ko ducts possess 35% fewer p63
+
 
myoepithelial cells than jnk2wt (Figure 3.1, p=0.0078), trend toward increased luminal 
cells by Cytokeratin 8/18 (Figure 3.2A), significantly higher proportion of ER
+
 luminal 
cells (Figure 3.3, p=0.011) staining.  In histology samples, the observation was also made 
that Cytokeratin 8/18 staining is more intense in jnk2ko ducts than jnk2wt.  To confirm 
this observation, mammary glands from both genotypes were harvested from seven week-
old virgin females.  Cells were then processed and digested with collagenase to yield 
mammary organoids, which consist of fat pad-free mammary epithelial cells with their 
underlying extracellular matrix and few stromal cells.  Organoids were then lysed for 
western blot to examine Cytokeratin 8/18 expression.  Western blot confirmed that higher 
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expression of Cytokeratin 8/18 is induced by loss of JNK2 expression in the mammary 
epithelium (Figure 3.2B). 
To better quantify the luminal and basal cell populations, individual cell CD49f 
and CD24 expression levels were measured using flow cytometry. For this assessment, 
mammary glands from jnk2ko and jnk2wt mice were dissociated to organoids and then 
trypsinized to create a single cell suspension.  Stromal cells, such as fibroblasts and 
immune cell populations were negatively selected using a lineage panel of antibodies.  As 
seen in the above experiments, jnk2ko glands contain a larger proportion of CD49f
Lo
 
CD24
+
 luminal cells (61%) as compared jnk2wt glands (36%, Figure 3.4, p<0.0001). A 
corresponding decrease in the CD49f
hi
 CD24
lo
 basal/myoepithelial cell population was 
also seen in jnk2ko mammary epithelial cell preparations (p<0.0001). 
3.2. INHIBITION OF LUMINAL POPULATIONS BY JNK2 IS CELL AUTONOMOUS 
 
Development and differentiation of the mammary gland is highly dependent upon 
the influence of hormones such as ER (see section 1.1).  The mice analyzed in the above 
experiments possess a systemic knockout of Jnk2, therefore there is a potential that the 
differentiation phenotype is caused by an alteration of the endocrine system.  In order to 
act within the mammary gland in a cell autonomous fashion, JNK2 must be expressed by 
mammary epithelial cells or cells of the stroma.  To determine the expression pattern of 
JNK2 in the mammary gland, adult glands were examined by immunofluorescence using 
an anti-JNK2 antibody.  This analysis shows that JNK2 is expressed in jnk2wt mammary 
glands and not in jnk2ko glands, throughout the mammary epithelium (Figure 3.5).  This 
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indicates that JNK2 is available and may act cell autonomously to prevent luminal cell 
differentiation. 
To further test if JNK2 affects differentiation and mammary growth independent 
of hormonal influence, mammary epithelial cells from both genotypes were isolated and 
cultured on  atrigel™ using defined growth media. This method has been shown to 
allow growth of single cells into spherical mammary 3-dimensional cultures that possess 
differentiative capability and recapitulate effects of gene targeting in vivo (25, 116).  
Cultures were allowed to grow and differentiate prior to analysis of cell populations.  
Consistent with observations that JNK2 inhibits luminal cell populations in vivo, the 
resulting jnk2ko cultures show fewer smooth muscle actin positive myoepithelial/basal 
cells and more Cytokeratin 8/18
+
 cells than jnk2wt controls (Figure 3.6). 
To determine the level of the mammary epithelial cell hierarchy is affected by 
JNK2, in vitro differentiation assays were performed.  Mammary glands from jnk2ko and 
jnk2wt mice were minced and sorted for mammary repopulating unit (stem cell enriched) 
and colony forming unit (progenitor enriched) populations, representing stem and 
progenitor fractions, respectively.  These were plated and allowed to grow and 
differentiate thus producing colonies of cells that define the particular lineage path that 
was taken by stem cells or revealing whether the progenitor was of bipotent, luminal, or 
basal lineage in the case of colony forming units.  Mixed-, luminal-only-, and basal-only 
colonies were produced from mammary repopulating- and colony forming units of both 
genotypes.  Mammary repopulating unit-enriched populations from jnk2ko were found to 
produce significantly more luminal colonies (Table 3.1, 2way ANOVA with Bonferroni 
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Post-test) and significantly fewer basal+mixed colonies, representing the sum of both 
basal groups.  There were no significant differences found in proportions of basal or 
mixed colonies.  Colony forming units-enriched populations from jnk2ko produced a 
lower proportion of basal-only colonies (Table 3.2, 2way ANOVA with Bonferroni Post-
test), but there were no other significant differences in luminal colony proportions.  These 
data further support that JNK2 promotes population of the mammary gland with the basal 
lineage while suppressing luminal populations.  Suppression of luminal lineage 
proportions appears to cause an effect at both stem and progenitor levels of the mammary 
hierarchy. 
3.3. JNK2 INHIBITS NOTCH-DEPENDENT LUMINAL CELL DIFFERENTIATION 
Lineage commitment and differentiation within the mammary gland is highly 
dependent upon the p63/Notch1 interaction (30).  When p63 expression is elevated, 
myoepithelial populations increase and when Notch1 expression increases, so do luminal 
cell populations. In jnk2ko mammary glands, luminal populations are increased as 
compared to jnk2wt controls.  The proportion of cells expressing p63 is also decreased by 
loss of JNK2.  Because, like Notch1, JNK2 appears to be important for regulation of 
luminal cell differentiation in both stem and progenitor levels of the mammary hierarchy, 
it was hypothesized that increased luminal populations in jnk2ko mammary glands are 
due to increased Notch activity.   
In order to become activated, transmembrane Notch receptors that are bound by 
their ligands must be cleaved at intracellular and extracellular domains (121).   The 
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intracellular cleavage event is mediated by Gamma Secretase, which allows the Notch 
intracellular domain (Notch
ICD
) to translocate into the nucleus to de-repress promoters of 
target genes, such as Hes1.  Highest levels of transcriptional activation are achieved by 
association with Mastermind-like proteins (122). 
To find if Notch signaling is increasing luminal differentiation in the jnk2ko 
model, were fixed and stained for fluorescence microscopy with cell lineage markers.  To 
determine if Notch signaling promotes proliferation and/or differentiation of jnk2ko 3-
dimensional cultures, primary mammary epithelial cells were seeded in  atrigel™ and 
treated with Gamma Secretase IX (GSI), an inhibitor of Notch receptor cleavage and 
activation.  GSI treatment trends toward increases in the proportion of p63
+
 myoepithelial 
cells in both jnk2wt and jnk2ko cultures compared to DMSO controls but only jnk2ko 
groups vary significantly (Figure 3.7, 2way ANOVA with Bonferroni Post-test). The 
proportion of p63
+
 cells is similar in jnk2ko and jnk2wt GSI treated cultures, which 
indicates that treatment has successfully eliminated effects of Notch signaling on 
differentiation.  Similar to results gained in assessment of Notch-dependent growth, the 
increase of myoepithelial cell proportion is greatest in jnk2ko cultures.  This indicates a 
greater dependence on Notch signaling for differentiation in these cells, as compared to 
jnk2wt. 
To evaluate the proportions of luminal cells that are affected by GSI treatment, 3-
dimensional cultures were stained with a Cytokeratin 8/18 antibody and positive cells 
were counted.  Consistent with the increase in myoepithelial cell proportion observed in 
the presence of GSI, proportions of jnk2ko luminal populations significantly decreased in 
 29 
jnk2ko cultures (Figure 3.8, 2way ANOVA with Bonferroni Post-test).  No significant 
alteration in luminal cell populations was observed in jnk2wt cultures.   
These data were further confirmed using a Adenoviral introduction of a dominant 
negative Mastermind gene (AdMAM51) (112).  In this experiment, normal mammary 
epithelial cells were isolated from jnk2ko and jnk2wt glands and then infected with 
adenoviruses encoding GFP (AdGFP) or AdMAM51 to reduce Notch-dependent 
transcription.  RNA harvested from 3 dimensional cultures showed a reduction in 
expression of the Notch target gene, Hes1, in response to AdMAM51 expression (Figure 
3.9A, 2way ANOVA with Bonferroni Post-test).  This finding confirms efficacy of the 
AdMAM51 activity.  Similar to GSI treatment, infection of jnk2ko mammary cells with 
AdMAM51 significantly decreased the diameter of cultures (Figure 3.9B, 2way ANOVA 
with Bonferroni Post-test).  AdMAM51 treatment also significantly decreased luminal 
cell populations of jnk2ko cultures (2way ANOVA with Bonferroni Post-test) without 
significantly affecting populations in jnk2wt cultures (Figure 3.10).  Collectively, these 
data indicate that jnk2ko MECs are more sensitive to Notch signaling inhibition, and 
JNK2 regulates mammary epithelial cell differentiation through the Notch pathway. 
3.3. JNK2 INHIBITS NOTCH-DEPENDENT MAMMARY CELL GROWTH 
 
Other reports show that increased Notch signaling leads to increased acinar 
growth (24, 25). To see if this is true in the jnk2ko model, mammary cells were grown in 
3-dimensional culture in the presence of GSI, as above.  At nine days post-seeding, 
cultures were imaged and measured.  As expected, GSI treatment significantly decreases 
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the final diameter of jnk2wt and jnk2ko 3-dimensional cultures, relative to the vehicle 
controls (Figure 3.11, 2way ANOVA with Bonferroni Post-test). Treatment with GSI 
causes jnk2wt and jnk2ko cultures to become essentially equal in diametric size.  The fact 
that jnk2ko cultures show a larger reduction in diameter with GSI than jnk2wt implies that 
they are more reliant on Notch signaling.  This could potentially be caused by an increase 
in magnitude of Notch signaling within jnk2ko mammary epithelial cells. 
3.5. JNK2 INHIBITS NOTCH1 EXPRESSION AND CLEAVAGE IN VIVO 
The importance of Notch signaling in mammary epithelial cell differentiation is 
well known.  The fact that Notch activity is highest in the terminal end buds of pubertal 
mammary glands also supports a role for Notch during pubertal mammary development 
(30). Moreover, all Notch receptors are expressed in the developing mammary gland but 
it is Notch1 that is temporally and spatially expressed in a pattern that best facilitates the 
process of differentiation (25).  As mentioned previously, Notch1 efficiently promotes 
luminal cell populations over myoepithelial/basal populations—similar to the effect of 
jnk2ko.  Since 3-dimensional culture experiments demonstrate that Notch signaling drives 
luminal commitment, Notch activity was assessed throughout puberty by performing 
immunohistochemistry, using a Notch1
ICD
 antibody. Because highest levels of Notch 
signaling occur in the terminal end buds, analyses were divided between mature ductal 
regions and terminal end buds themselves.  No differences in Notch1
ICD
 expression are 
detected in mature ducts (Figure 3.12).  However, within the putative mammary stem cell 
niche of terminal end buds, the proportion of cells staining positive for Notch1
ICD
 is 
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higher in jnk2ko glands, compared to jnk2wt, throughout puberty (Figure 3.13, 2way 
ANOVA with Bonferroni Post-test). 
To validate that increased Notch1
ICD
 expression in jnk2ko pubertal glands results 
in higher Notch-dependent transcription, mammary organoids were isolated from jnk2ko 
and jnk2wt mammary glands and harvested to collect RNA.  The expression of Hes1 was 
measured using qPCR. This experiment revealed that jnk2ko organoids express 10.5 
times more Hes1 mRNA than jnk2wt, thus confirming increased Notch activity in the 
absence of JNK2 expression (Figure 3.14A, p=0.0093).  Further qPCR experiments 
revealed that Notch1 mRNA is also significantly elevated in jnk2ko organoids (Figure 
3.14B, p<0.0001), and western blotting of protein isolated from mammary organoids 
shows an increase in full-length Notch-1 protein as compared to jnk2wt (Figure 3.14C). 
3.6. DISCUSSION 
Our data are consistent for a role of JNK2 in negative regulation of Notch1-
dependent luminal cell differentiation.  However, the jnk2ko phenotype observed does 
not agree with all reports of increased Notch signaling in the mammary gland.  For 
example, mammary-specific overexpression of active Notch-1, -3, or -4 leads to 
tumorigenesis through overgrowth of luminal progenitors (123, 124).  Many generations 
of jnk2ko mice have been observed and these mice to not show a propensity to develop 
mammary tumors, in spite of the increased luminal populations observed in the above 
experiments.  This is likely due to disparate levels of Notch signaling in the jnk2ko and 
Notch receptor overexpression models.  A recent study examining the effect of Notch1
ICD
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expression in 3-dimensional cultures revealed a dose-dependent mammary growth 
phenotype (125).  The highest levels of Notch1
ICD
 expression are associated with small 
and abortive cultures that were not seen in our experiments.  The jnk2ko 3-dimensional 
culture phenotype is more reminiscent of large, hyper-proliferative cultures that were 
associated with lower Notch1
ICD 
overexpression.  This level of expression may be more 
physiologically relevant and give a more appropriate picture of the role of Notch in 
mammary development.  
Spatio-temporal localization of Notch1
ICD
 is also of critical importance in 
differentiation of mammary epithelial cells.  Reports show that highest Notch1 expression 
in the mammary gland is during puberty with the most intense activity in terminal end 
buds (30).  Because terminal end buds are the site of mammary stem cells, they are an 
ideal structure for differentiation to begin.  Consistent with this, highest levels of 
Notch1
ICD
 expression is localized to the terminal end buds in jnk2ko mice.  Because of 
the biphasic nature of Notch1-dependent luminal commitment, in promotion of stem cell 
differentiation and at the level of progenitor expansion, further experiments into the 
precise steps affected by JNK2 may be warranted.  Although mammary repopulating unit 
populations were not validated by in vivo transplantation experiments, they agree with 
our differentiation data and show that this enriched population results in the production of 
luminal cells at a higher frequency in jnk2ko as compared to jnk2wt mammary glands.  
Colony forming unit results also support our in vivo differentiation results, but in an 
unexpected way. Here, equal numbers of luminal colonies and fewer basal colonies were 
seen in jnk2ko preparations.  The remaining colonies were of mixed lineage, supposedly 
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bipotent progenitor enriched.  Jnk2ko cultures had significantly more of these mixed 
colonies and presumably, a higher proportion of luminal cells as a result.  The presence 
of JNK2 protein in all cell types of the mammary epithelium and the role of Notch1 in 
both stem cell- and progenitor differentiation processes support JNK2 regulates both 
levels of the mammary hierarchy as well.  
JNK-Notch interactions have been studied in a variety of tissues with unique 
results depending upon the system.  The results point to a dichotomous relationship 
wherein JNKs regulate Notch signaling differentially depending upon whether or not it 
has been activated by an external stimulus.  For example, treatment of mice by 
intraperitoneal injection of JNK inhibitor induces cleavage of the Notch-1 receptor in 
normal brain tissues (126).  Similarly inhibition of JNK in macrophage cell lines induces 
increased Notch signaling by upregulating Jagged-1 (127).   Conversely, treatment of 
HEK293 cells with various cytokines induces Notch1 cleavage and requires JNK (128).  
In this system, JNK activity was induced by the cytokines.  In Kaposi’s sarcoma 
endothelial cells, JNK is induced by contact inhibition to promote Hes1 transcription, 
independent of Notch receptor activation (129).  Notch also reciprocally regulates JNK 
activity in HEK293 cells by preventing UV-induced activation of JNK1 and JNK3 by 
binding to and inhibiting the scaffold activity of JIP-1 (130).  This prevents JNK-induced 
apoptosis.  Our model required no external input of stimulus and seems to be in 
agreement with reports that basally active JNKs inhibit Notch signaling.  
Our model indicates that the highest level of regulation over the Notch pathway, 
by JNK2, is in transcription of the Notch1 gene.  A recent report in keratinocytes has 
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suggested a potential mechanism for this interaction.  This showed that MAPK signaling 
negatively regulates expression of Trp53 mRNA through AP-1 (131).  In this report, 
EGF-induced ERK signaling was the regulating MAPK, but JNKs have been cemented as 
key regulators of AP-1 and they are, themselves, activated in response to EGF.  This may 
be a potential mechanism, but in light of the previous paragraph may present mixed 
results because active JNKs seem to promote Notch1 activity. 
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Chapter 4 – JNK2 Inhibits Luminal Differentiation and Notch signaling 
in the Polyoma Virus Middle T Antigen (MT) Model 
 
 
 
4.1. JNK2 INHIBITS LUMINAL CELL DIFFERENTIATION IN MT TUMORS 
In order to characterize the signaling involved in JNK2-dependent inhibition of 
Notch1 mRNA expression, cell lines and tumors that were developed while studying the 
MT model of mammary tumorigenesis were utilized (3, 6).  Because normal mammary 
and tumor differentiation are controlled by similar mechanisms, it was hypothesized that 
JNK2 inhibits luminal lineage commitment in MT tumors through inhibition of Notch 
signaling.  To test this hypothesis, tumors from MT
+
 jnk2ko and MT
+
 jnk2wt mice were 
sectioned and immunostained with p63 or Cytokeratin 8/18 antibodies to identify 
basal/myoepithelial and luminal cells, respectively.  Results show that a high proportion 
of tumor cells do not express either p63 or Cytokeratin 8/18, an indication that these 
tumors became less differentiated as they developed—a characteristic that is typical of 
advanced tumors.  Of cells that did show positive staining, MT
+
 jnk2ko tumors have a 
significantly smaller proportion of cells with nuclear p63
 
staining (Figure 4.1, p=0.0079) 
and a greater proportion of Cytokeratin 8/18
+
 cells than MT
+
 jnk2wt tumors (Figure 4.2, 
p=0.0411 Mann Whitney test). These results suggest that, akin to the normal mammary 
gland, JNK2 promotes basal lineage commitment while suppressing the luminal lineage 
in MT tumors. 
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4.2. JNK2 INHIBITS EGF-DEPENDENT NOTCH SIGNALING IN MT TUMORS AND CELLS  
Next, MT tumors sections were immunostained for Notch1
ICD
 to address the 
hypothesis that Notch signaling is suppressed by JNK2 in MT tumors.  This analysis 
reveals that while MT
+
 jnk2wt tumors are virtually Notch1
ICD
 negative, MT
+
 jnk2ko 
tumors express the cleaved Notch1 receptor in nearly all cells (Figure 4.3).  Additionally, 
qPCR shows that Notch1 mRNA expression is four times higher in MT
+
 jnk2ko tumors as 
compared to MT
+
 jnk2wt tumors (Figure 4.4, p=0.0101).  This assessment verifies that 
Notch signaling is inhibited by JNK2 in cells of MT tumors, similar to normal mammary 
epithelial cells.   
Further exploration of the mechanism by which JNK2 inhibits Notch1 mRNA 
expression and activity was performed using an MT
+
 jnk2ko cell line that was previously 
generated (3).  This cell line is modified to express a GFP-JNK2 fusion protein or GFP 
control.  RNA was isolated from confluent cells in culture and assessed by qPCR.  
Consistent with results found in normal glands and MT tumors, GFP-JNK2 expression 
suppresses Notch1 by 42% (Figure 4.5A, p=0.0005).  Western blotting confirmed that 
GFP-JNK2 expression suppresses full-length Notch1 receptor at the protein level in MT 
cells (Figure 4.5B). Additionally, there is a trend toward reduction of Hes1 mRNA in 
GFP-JNK2 cells (Figure 4.5C). These results show that expression of and signaling 
through Notch1 is inhibited by JNK2 expression in MT cells. 
Previous work in keratinocytes showed that MAPK signaling inhibits Notch1 
mRNA expression through transcriptional repression of Trp53, the gene encoding p53 
(131).  These experiments show that MEK-1 and ERK suppress Notch1 expression in 
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response to EGF-mediated activation.  Although the authors did not observe any effects 
after JNK inhibition, this may have been a tissue specific interaction.  Because JNKs 
have been shown to become activated in response to EGF in breast cancer cells (61), I 
hypothesized that JNK2 inhibits Notch1 expression through suppression of Trp53 
transcription.  To test this hypothesis, expression levels of Trp53 mRNA in MT cells 
were examined.  RT-PCR showed that GFP-JNK2 inhibits Trp53 expression (Figure 
4.6A).  To verify that this also occurs in normal mammary glands, organoid mRNA was 
assessed by qPCR for Trp53 expression.  This showed that jnk2ko mammary glands 
express nearly three times more Trp53 mRNA than jnk2wt glands (Figure 4.6B, 
p=0.0004). 
To determine if suppression of p53 by JNK2 is through EGF signaling, MT cells 
were treated with 50ng/mL EGF and harvested for mRNA.  In this experiment, qPCR 
was performed to examine expression levels of Trp53 and Notch1.  Expression of 
Cyclind1 was also assessed as a positive control for EGF-dependent transcription (132).  
As expected, EGF treatment significantly increased expression of Cyclind1 in both MT
+
 
GFP-JNK2 and MT
+
 GFP cells against serum free media controls (Figure 4.7A, 2way 
ANOVA with Bonferroni Post-test), thus showing that EGF treatment is successfully 
inducing EGFR activity.  EGF treatment did not significantly affect expression of either 
Notch1 or Trp53 in MT+ GFP-JNK2 cells, but instead induced 2.11 times more 
expression of Trp53 and 30.6 times more Notch1 in MT
+
 GFP cells (Figure 4.7B and C, 
2way ANOVA with Bonferroni Post-test).  Serum free media controls were not 
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significantly different from each other.  These data show that JNK2 suppresses EGF-
dependent promotion of Trp53 and Notch1 mRNA expression. 
4.3. JNK2 INHIBITS EGF-DEPENDENT ACTIVATION OF NOTCH1 PROMOTER ACTIVITY 
THROUGH P53 RESPONSE ELEMENTS 
 
To assess whether JNK2-dependent inhibitions of Trp53 and Notch1 expression 
are related, notch1 promoter assays were performed.  The notch1 promoter contains two 
p53 response elements that are bound by p53 to potentiate its transcription (113). Because 
MT tumors and cell lines express wildtype p53 (3), I hypothesized that p53 binds to the 
promoter of notch1 in MT cells in a manner that is suppressed by JNK2 expression. This 
mechanism was explored by transfecting MT
+
 GFP and MT
+
 GFP-JNK2 with Notch1 
promoter constructs driving expression of luciferase. These plasmids were previously 
designed and assessed for activity (113).  Three constructs were transfected into cells, 
individually:  full-length Notch-1 promoter (N1PR), Notch-1 promoter with mutated p53 
response elements (N1PRmut), or a control promoterless construct (N1PRless). As 
expected, MT
+
 GFP cells have higher Notch1 promoter activity than MT
+
 GFP-JNK2 
cells (Figure 4.8A, 2way ANOVA with Bonferroni Post-test).  This higher expression 
was significantly decreased to MT
+
 GFP-JNK2 levels in cells transfected with N1PRmut.  
Promoter activity in MT
+
 GFP cells was not affected by mutation of the p53 response 
elements, indicating that these are not important in promotion of Notch1 in these cells.  
These data support that JNK2 inhibition of Notch1 requires the p53 response elements 
within its promoter. 
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  Next, the effect of EGF treatment on Notch1 promoter activity was assessed.  
Similar to data gained in the qPCR experiment above, EGF-stimulated N1PR activity was 
suppressed by expression of GFP-JNK2 (Figure 4.8B, 2way ANOVA with Bonferroni 
Post-test).  Additionally, EGF-stimulated N1PR activity was abolished by mutation of 
p53 response elements in the Notch1 promoter in MT
+
 GFP cells.  Surprisingly however, 
was the finding that mutation of p53 response elements in serum free media caused 
significant increases in Notch1 promoter activity in both MT
+
 GFP-JNK2 and MT
+
 GFP 
cells.  These data suggest that the Notch1 promoter is both positively and negatively 
regulated through its p53 response elements.  Negative regulation appears to be EGF and 
JNK2-dependent, but positive regulation is JNK2-independent. 
 To determine if decreased expression of Trp53 mRNA in MT
+
 GFP-JNK2 cells 
also leads to decreased binding of p53 to the Notch1 promoter, chromatin 
immunoprecipitation was performed.  Primers were designed using the sequence of the 
Notch1 promoter and aligned around the p53 response elements.  As a positive control for 
p53 binding, primers were also designed around p53 response elements of the Cdkn1a 
(the gene encoding the cyclin-dependent kinase inhibitor, p21) promoter and the 
glyceraldehyde phosphate dehydrogenase (Gapdh) promoter was used as negative 
control.  Chromatin was purified from MT
+
 GFP and MT
+
 GFP-JNK2 cell lysates and 
Chromatin immunoprecipitation was performed using an anti-p53 antibody or IgG 
control.  Input controls show similar loading of MT
+
 GFP and MT
+
 GFP-JNK2 samples 
and IgG antibody control shows no amplification, as expected (Figure 4.9).  
Amplification with Cdkn1a promoter positive control primers shows that p53 was 
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successfully immunoprecipitated and that GFP-JNK2 inhibits binding of p53 to the 
Cdkn1a promoter.  Notch1 promoter primers show that p53 binds to the Notch1 promoter 
at a greater frequency in MT
+
 GFP cells than MT
+
 GFP-JNK2 cells, thus demonstrating 
that JNK2 inhibits binding of p53 to the Notch1 promoter.  Experiments above suggest 
that decreases in binding of p53 to the Notch1 promoter, in the presence of GFP-JNK2, 
are caused by inhibition of transcription of p53 mRNA. 
4.4. DISCUSSION 
Data presented in this chapter support that JNK2-dependent differentiation 
mechanisms that are present in the normal mammary gland are also present in tumors.  
Specifically, these data show that JNK2 inhibits luminal populations in the MT model. 
Our results were limited by the overall lack of differentiation in archived tumors, 
presumably because of the advanced size and subsequent dedifferentiation.  However, a 
sufficient proportion of cells maintained expression of Cytokeratin 8/18 and p63 to 
produce a meaningful result that mirrors the effects of JNK2 in normal mammary tissue. 
In other mouse models, overexpression of Notch1
ICD
 has been shown to cause the 
generation of tumors due to a build-up of luminal progenitor cells.  Given the decreased 
tumor latency phenotype observed (3) and preponderance of Notch1
ICD
 positive cells in 
MT
+
 jnk2ko tumors, it is reasonable to hypothesize that Notch signaling plays a role in 
increasing the susceptibility to tumorigenesis in this model.  This may be a direct effect, 
such as increasing the proliferative capacity of cells or an indirect effect, through 
modulation of the differentiation programme.  A larger luminal population in jnk2ko 
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glands may enhance tumor susceptibility when confronted with oncogenic stimuli, as 
luminal cells are the target for tumorigenesis in the MT model.  This could lead to both 
the decreased tumor latency and increased multiplicity phenotypes of MT
+
 jnk2ko mice.  
Our results show that Trp53 mRNA is upregulated by jnk2ko in both normal 
mammary and MT tumor cell models.  This contrasts with a recent result that MKK7 
ablation in Kras induced lung tumors and NeuT oncogene induced tumors causes 
destabilization and degradation of p53 (133).  The results in this report were corroborated 
using jnk1+/- jnk2ko mice, but jnk2ko alone had no effect on p53 protein expression.  The 
oncogenic stimuli used in these experiments are unique from ours and it is worth noting 
that MT expression is silenced in our MT
+
 cell lines due to methylation (unpublished 
data).  This means that our signaling mechanism exists in the absence and presence of 
oncogenic activation, thus showing that the JNK2/Notch1 interaction is the result of basal 
JNK activity.   
The question of whether p53 is the protein mediating Notch1 upregulation in the 
absence of jnk2 expression has not been answered by these experiments completely.  We 
have shown conclusively that the p53 response elements within the Notch1 promoter are 
essential for upregulation and that p53 binding is increased to the promoter.  However, 
p63 is also able to bind to the p53 response elements (113) and is known to counteract 
Notch1 expression (30).  Because p63 expression is decreased by jnk2ko in both the 
normal and MT models, there remains the potential that Trp63 expression may be 
promoted by JNK2 and the absence of JNK2 decreases its expression thus allowing 
Notch1 expression to rise.  
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Chapter 5 – JNK2 Inhibits ER+ Luminal Cell Differentiation Through 
Promotion of EMT in a Trp53-null Model 
 
 
 
5.1.  JNK2 PROMOTES PROLIFERATION OF TRP53-NULL TUMORS 
In order to test the hypothesis that JNK2 inhibits Notch-dependent luminal cell 
differentiation through the inhibition of Trp53 transcription, the Trp53-null model was 
used.  Mice harboring p53ko mutations have a propensity toward development of 
lymphoma and sarcoma but few develop mammary tumors (110, 134, 135).  To 
circumvent the lethality caused by tumors of other types, p53ko mammary glands were 
isolated from sexually mature p53ko females and transplanted into fat pads of 3 week-old 
wildtype virgin female mice. Tumors generated by p53ko transplants have been shown to 
differentiate into most of the tumor subtypes, so this an ideal model for assessing JNK2-
dependent lineage regulation (53). 
Jnk2wt and jnk2ko mice were crossed with p53ko mice to obtain p53ko;jnk2ko 
mammary glands for transplantation. Similar to data recently reported comparing 
p53ko;jnk2wt and p53ko;jnk2ko systemic mutant mice (5), no significant difference in 
tumor latency was noted (Figure 5.1).  However, p53ko;jnk2ko tumors grow significantly 
faster than p53ko;jnk2wt tumors (Figure 5.2A, p<0.0003, Logrank Test). Histology 
confirms that increased tumor growth is due to elevated proliferation rate, as 
p53ko;jnk2ko tumors exhibit 2.9 times more Ki-67 positive cells compared to 
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p53ko;jnk2wt (Figure 5.2B, p=0.0159).  Microarray analysis found that expression of 
Prediction Analysis of Microarray (PAM)50 Proliferation genes (136) is higher in the 
p53ko;jnk2ko tumors, which further supports that JNK2 inhibits p53ko tumor 
proliferation (Figure 5.2C, p=0.0101).  These data indicate that while JNK2 does not 
have a role in promoting or suppressing tumorigenesis, it is important for suppressing 
tumor growth in later stages of tumor progression. 
5.2.  JNK2-DEPENDENT INHIBITION OF NOTCH SIGNALING REQUIRES P53 
As is characteristic of the p53 null transplant model, gene expression is quite 
heterogeneous among tumors generated.  Because JNK2 inhibits notch1 expression in 
normal mammary glands and MT tumors that express wildtype p53, it was hypothesized 
that notch1 expression would not be suppressed in the absence of p53.  Analysis by qPCR 
shows that expression of Notch1 is highly variable in p53ko tumors and does not 
significantly differ between tumor genotypes (Figure 5.3A).  Microarray analysis also 
failed to detect significant differences in Notch1 expression (1.1-fold increase, FDR 54%, 
data not shown). This demonstrates that JNK2 no longer suppresses expression of Notch1 
in Trp53-null tumors. 
To look at JNK2/Notch1 interactions in a system with lower variability, a primary 
cell line was generated from one of the p53ko;jnk2ko tumors. As with the MT cell lines, 
GFP-JNK2 or GFP alone were stably expressed using lentiviral infection and selected for 
highest the expressing clone. As with MT tumor cells, p53ko;jnk2wt and p53ko;jnk2ko 
cells were transfected with either N1PR, N1PRp53mut, or N1PRless and CMV-beta 
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galactosidase control plasmid. As seen in tumors, Notch1 promoter activity is not affected 
by expression of GFP-JNK2 (Figure 5.3B).  These data further support that inhibition of 
p53 is necessary for JNK2 to reduce Notch1 transcription. 
5.3. JNK2 INHIBITS LUMINAL CELL DIFFERENTIATION OF P53 NULL TUMORS 
Since Notch1 expression is not inhibited by JNK2 in the absence of p53, it was 
hypothesized that tumor histology does not differ between p53ko;jnk2ko and 
p53ko;jnk2wt tumors.  To assess if luminal lineages are altered by JNK2 expression in 
these tumors, sections were immunostained with a Cytokeratin 8/18 antibody.  As with 
MT tumors, a large proportion of cells within tumors are negative for this marker. 
Surprisingly, the proportion of Cytokeratin 8/18
+
 cells is significantly elevated in 
p53ko;jnk2ko tumors as compared to p53ko;jnk2wt (Figure 5.4A, p=0.0159).  This is 
similar to our findings in normal mammary glands and MT tumors.  
To confirm that luminal cell populations are elevated in p53ko;jnk2ko tumors, 
lineage markers were assessed by qPCR.  This approach revealed that loss of jnk2 causes 
a trend toward down-regulation of basal related genes (Trp63 and Krt14) and significant 
up-regulation of the luminal marker, Brca1 (Figure 5.4B, p=0.05).  Expression of Brca1 
differed most strongly between the two genotypes and was also noted by tumor 
microarray (BRCA1 elevated 2.16-fold, 4.38% FDR) along with alterations in the 
ATM/BRCA1 pathway using Gene Set Enrichment Analysis (GSEA) (Figure 5.5).  
These data suggest that even in the absence of p53/Notch1 interactions, loss of JNK2 
increases luminal populations. 
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Further exploration of the mechanism behind JNK2-dependent differentiation in 
the absence of p53, the p53ko;jnk2ko cell line with GFP or GFP-JNK2 expression was 
used.  RNA was isolated from cell lines and assessed for expression of Trp63, Krt14, and 
Brca1.  Similar to tumors, GFP cells trend toward expression of lower levels of Krt14 
and Trp63, as well as significantly increased expression of Brca1 (Figure 5.6A, 
p=0.0205).  To confirm that BRCA1 transcription is inhibited by JNK2, p53ko;jnk2ko 
GFP and GFP-JNK2 cells were transfected with either a brca1 promoter plasmid 
(BRCA1 PR) driving expression of luciferase or PRless control plasmid. Again, this 
revealed that GFP-JNK2 reduces Brca1 promoter activity compared to the GFP control 
(Figure 5.6B, 2way ANOVA with Bonferroni Post-test).   To assess the role of p53 in this 
process, Brca1 expression was examined by qPCR in MT tumors.  This revealed no 
significant difference in expression (Figure 5.7), further suggesting that Brca1 is a JNK2 
target in the absence of p53 expression.  These data show that JNK2 inhibits luminal 
lineage commitment independent of p53/Notch1 interactions. 
5.4.  BRCA1 EXPRESSION AND EMT GENE SIGNATURE ARE ANTI-CORRELATED 
To explore potential mechanisms that contribute to the suppression of luminal 
characteristics by JNK2, human breast tumor datasets were consulted.  Given the 
established role of BRCA1 in the luminal differentiation, the correlation between 
Brca1mRNA expression and a stem/EMT signature was examined in human datasets.  
For this analysis, the average value of a set of genes that increase in expression during 
EMT was calculated for each individual tumor in the datasets and then tumors were 
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ranked by expression level (137).   ach tumor’s specific expression level of Brca1 
expression was then plotted against these values to see the correlation between EMT and 
Brca1.  Figures 5.8A and B show that there is a significant anti-correlation between 
Brca1 and EMT in both the UNC308 (Pearson correlation -0.215, p=0.000147) and 
COMBINED855 (Pearson correlation -0.246, p=2.75e
-17
) human datasets.  To verify that 
this same relationship occurs in our mouse tumors, this comparison was again made using 
microarray data from both p53ko;jnk2ko and p53ko;jnk2ko transplanted mice.  The same 
trend was observed, although not significantly due to low numbers of tumors assessed 
(Figure 5.8C, Pearson correlation -0.444). These data are consistent with the role of 
BRCA1 in later stages of mammary cell differentiation and suggest the potential that 
EMT genes and BRCA1 antagonize the transcription of each other. 
5.5. JNK2 PROMOTES EMT AND TUMOR INITIATING POPULATIONS 
It was next hypothesized that if EMT and Brca1 have opposing functions, JNK2 
must promote EMT.  To test this hypothesis, mRNA expression differences of select 
EMT/stem-related genes were then assessed by qPCR in Trp53-null tumors and cell lines.  
In these experiments, p53ko;jnk2ko tumors show trends toward lower expression of 
Twist1, Snai1, and Klf4 and significantly downregulated Zeb1 (p=0.0105) and Snai2 
(Figure 5.9A, p=0.0336). Expression of Cdh1 (the gene transcribing e-cadherin) was 
significantly elevated in p53ko;jnk2ko tumors (p=0.0268). Comparison of p53ko;jnk2ko 
GFP and GFP-JNK2 cell lines further support that JNK2 promotes EMT.  This 
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experiment showed that expression of Zeb1 is significantly decreased by GFP-JNK2 
expression (p=0.0315), however remaining genes appear unchanged (Figure 5.9B).  
More comprehensive analysis of EMT-related genes was carried out with 
microarray-based comparison of the GFP and GFP-JNK2 cell lines.  This analysis 
identified several other EMT-related gene targets (Figure 5.10A) that were validated by 
western blot (Figure 5.10B).  GFP-JNK2 promotes higher expression of Zeb1, Six1, 
Lef1, Vimentin, and MMP9. Notably, although full length e-cadherin protein and its 
cleavage products are present in both GFP and GFP-JNK2 cells, it is less abundant in 
GFP-JNK2 cells.  These data show that JNK2 promotes expression of genes that are 
associated with EMT. 
The presence of e-cadherin in both cell lines necessitated that the expression 
pattern be visualized in cells by immunofluorescence to see if it is homogeneous or 
segregated into discrete populations.  This experiment showed that two distinct 
populations exist within the GFP-JNK2 expressing cell line:  one that expresses e-
cadherin and one that does not (Figure 5.11A).  Similarly, two populations can be 
discerned when analyzing Vimentin expression (Figure 5.11B).  Bright field microscopy 
also revealed that GFP-JNK2 cells in culture grow as foci, thus demonstrating they are 
less prone contact inhibition than GFP cells—further supporting that an EMT population 
exists in the GFP-JNK2 cell line (Figure 5.12).   
E-cadherin and Vimentin expression appear to discriminate between two separate 
populations in GFP-JNK2 cells, but immunocytochemistry could not confirm this 
because the primary antibodies were raised in the same species. To test the possibility 
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that two distinct populations exist in GFP-JNK2 cells, CD24 and CD49f expression 
levels were measured. CD24
-/Lo
 and CD49f+ populations have been identified by many as 
a mesenchymal population in mouse mammary tumor models (138, 139).  CD49f 
positivity does not differ between GFP and GFP-JNK2 cells, whereas CD24 expression is 
markedly different. GFP cells are almost exclusively CD49f
+
/CD24
+
 (98%) whereas 
GFP-JNK2 cells contain a CD49f
+
/CD24
+
 (21%) population and a significant 
CD49f
+
/CD24
-
 (77%) population (Figure 5.13).  The CD49f
+
/CD24
-
 population is 
significantly larger in GFP-JNK2 cells than in GFP cells (2way ANOVA with Bonferroni 
Post-test). To find if the two populations are generated due to differential expression of 
GFP-JNK2, flow cytometry was performed comparing GFP levels to CD24 expression.  
When cells are gated for medium and high GFP intensity, high GFP-JNK2 expression is 
associated with CD24
-
 cells (Figure 5.14).  These data show that high expression of JNK2 
leads to induction of EMT and a putative tumor initiating cell population in Trp53-null 
cells. 
We next wished to verify that the CD24
+
 population is less mesenchymal than the 
CD24
-
 population.  To accomplish this, GFP-JNK2 cells were sorted on the basis of 
CD24 positivity and then each population was lysed for RNA isolation.  The same gene 
panel as above was used in this analysis.  We found that the CD24
+
 population has lower 
expression  of markers Mesenchymal cells, Twist1 (p=0.0484), Klf4 (p=0.0439), and 
Snai2 (p=0.0233) and higher levels of markers of differentiation—Brca1 (p=0.05 Mann 
Whitney test), Krt14 (p=0.0018, Mann-Whitney test) and Cdh1 (Figure 5.15A, p=0.0131, 
Mann-Whitney test). We also assessed expression of Gata-3, a transcription factor that 
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promotes luminal cell commitment (35), using RT-PCR. Like other markers of 
differentiation, its expression is higher in the CD24
+
 population (Figure 5.15B). This data 
show that the CD24+ population consists of cells with both luminal and basal 
characteristics, but low expression of EMT genes.  This population is thus more 
differentiated than the EMT-rich CD24
-
 population with low expression of luminal and 
basal genes.  Because GFP-JNK2 expression is highest in the CD24- population, this data 
also shows that JNK2 antagonizes differentiation by inducing EMT in the absence of p53. 
5.6.  JNK2 PROMOTES METASTASIS AND TUMOR INITIATING CELL POPULATIONS 
EMT promotes tumor initiating cell populations that are comparatively less 
differentiated than other non-EMT populations (140).  Because GFP-JNK2 expression 
promotes an EMT populations, I hypothesized that it might also enrich the p53ko;jnk2ko 
cells in tumor initiating cells.  To test this hypothesis, limiting dilutions of GFP and GFP-
JNK2 cells were made and delivered to nude mice.  The dilutions selected were 10,000-, 
1,000-, and 100 cells per mouse.  All mice from both genotypes produced palpable 
tumors at the 10,000 cell dilution (Table 5.1).  Only one of four mice injected with GFP-
JNK2 cells produced a palpable tumor while no GFP cell injected mice produced tumors 
at this dilution.  No mice injected with either genotype of cell line produced palpable 
tumors at the 100 cell dilution.  No metastases were produced from palpable tumors of 
GFP cell injected mice, but two metastases were detected by GFP fluorescence in GFP-
JNK2 injected mice. 
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After six months, many mice from each genotype had not produced palpable 
tumors.  To assess the potential that injected cells were still viable and had produced non-
palpable tumors, mice were harvested and examined with fluorescence microscopy 
(Table 5.2).  No additional tumors were detected in GFP cell injected mice, but one 
contra-lateral gland metastasis was seen at 100 cell dilution without a primary tumor.  
Five more tumors were found in GFP-JNK2 injected mice, with one at 1000 cell dilution 
and four at 100 cell dilutions.  One contralateral gland metastasis was seen in each of the 
1000 and 100 cell dilution groups.  Additionally, ascites developed in one of the 1000 
cell injected GFP-JNK2 group.  This was detected in the absence of a primary tumor. 
Data from this experiment were used to calculate tumor initiating cell frequency 
using calculation software (Table 5.3).  This showed that the GFP cell line has an average 
of 1 tumor initiating cell in 5,116 cells.  This is considerably lower than the GFP-JNK2 
cell line, where tumor initiating cells were found at a frequency of 1 in 569 cells 
(p=0.0305, Pearson’s Chi-squared Test).  This experiment shows that GFP-JNK2 
expression not only promotes tumor initiating cell populations, but also metastasis.  As 
previously shown by other groups, these two characteristics are likely a result of the role 
of JNK2 in promotion of EMT. 
5.7. BRCA1 ANTAGONIZES JNK2-DEPENDENT TUMOR INITIIATING CELL 
POPULATIONS 
 
To directly assess the potential that BRCA1 and EMT antagonize each other, 
p53ko;jnk2ko cells were co-infected with either GFP-JNK2 and BRCA1 viruses or 
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transiently transfected with GFP and Zeb1.  Zeb1 and BRCA1 were chosen because they 
are the genes that are most consistently affected by JNK2 expression and BRCA1 was 
shown to antagonize EMT in silico (see section 5.4).  Cells were selected and then 
analyzed by flow cytometry for variable expression of CD24 and CD49f against GFP-
JNK2 alone cells.  It was hypothesized that ZEB1 expression would increase the CD24
-
 
population of GFP cells while BRCA1 expression would decrease the CD24
-
 population 
of GFP-JNK2 cells.  We found, remarkably, that expression of BRCA1 in GFP-JNK2 
cells is sufficient to lower the CD24
-
 population from 77% to <1% (Figure 5.16, 
p<0.0001).  ZEB1 expression decreased the magnitude of CD24 positivity in GFP cells 
but did not significantly affect the proportion of CD24- cells. This may be due to the 
transient nature of the ZEB1 expression and insufficient selection as a result.  This 
experiment shows that BRCA1 is sufficient to suppress JNK2-dependent EMT 
populations and suggests that it may be a major target of downregulation by JNK2 to 
bring about this phenotype. 
To see if EMT is affected by JNK2 expression in the absence of Brca1 expression 
changes, MT tumor RNA from MT
+
 jnk2wt and MT
+
 jnk2ko mice was analyzed for 
expression of select EMT markers by qPCR.  No significant differences in Cdh1, Snai1, 
Snai2, or Klf4 were seen by this analysis (Figure 5.17A-D).  These data support that p53 
inhibits promotion of EMT populations by JNK2. 
5.8. JNK2 INHIBITS ER-DEPENDENT GROWTH OF TRP53-NULL CELLS 
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As with p53ko tumors, proliferation is inhibited by expression of GFP-JNK2 in 
p53ko;jnk2ko cells (Figure 5.18A, 2way ANOVA with Bonferroni Post-test).  These 
findings are consistent with the properties EMT/tumor initiating cell populations that are 
induced by JNK2.  To examine if the JNK2-dependent effects on proliferation are 
secondary to its ability to induce EMT, cells were pulse labeled with BrdU for 24 or 48 
hours and sorted into CD24
-
 and CD24
+
 populations.  Results were similar for both time 
points.  In both GFP and GFP-JNK2 samples, the CD24
+
 population constitutes a higher 
fraction of BrdU
+
 cells than the CD24
-
 population (Figure 5.18B, 2way ANOVA with 
Bonferroni Post-test).  Moreover, both the CD24
+
 and CD24
-
 GFP-JNK2 cells 
incorporate less BrdU compared to GFP cells, indicating that JNK2 slows proliferation in 
both an EMT-dependent and -independent fashion. 
In rationalizing why the CD24
+
 population displays a higher proliferation rate in 
spite of showing evidence of more luminal differentiation, it was suspected that ER could 
modulate this response, especially given its elevated expression in GFP cells (Figure 
5.19A).  GFP cells also express higher levels of the ER target gene, PR, as compared to 
GFP-JNK2. As in human tumors, co-expression of ER and PR in GFP cells potentially 
indicates ER-responsiveness in these cells.  To validate this functional importance of ER, 
cells were cultured in 5% charcoal stripped serum and exposed to estradiol (E2) or 
E2+fulvestrant, a drug that degrades ER protein. After 24 hours of treatment, ER protein 
is notably reduced in GFP cells treated with E2+fulvestrant, whereas E2+fulvestrant 
treatment of GFP-JNK2 cells show no change in ER (Figure 5.19B).  This data show that 
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GFP cells are more ER responsive than GFP-JNK2 cells and that JNK2 inhibits ER 
expression. 
 To evaluate the effect of JNK2 on ER-dependent proliferation, GFP and GFP-
JNK2 cells were cultured in 10% FBS with or without fulvestrant for several days. 
Fulvestrant significantly inhibits GFP cell viability on day 3 and 6 of treatment, but GFP-
JNK2 cells show no significant growth inhibition (Figure 5.19C, 2way ANOVA with 
Bonferroni Post-test). These data indicate that JNK2 inhibits ER expression and ER-
associated proliferation.  Since ER expression is uncommon in mouse derived mammary 
tumors, its expression was measured in paraffin embedded p53ko tumors and did not 
identify any other tumors with ≥10% ER+ cells (data not shown). No tissue is available 
for the tumor from which the cell line was derived, but protein lysate from the first 
passage confirms ER expression.  
5.9.  DISCUSSION 
The majority of breast tumors possess a mutation in the gene encoding p53 or 
regulators of its activity.  Breast tumors with these mutations are commonly 
undifferentiated and invasive (39, 55, 118, 141-143).  The role of p53 in inhibition of 
stemness is a likely contributor to this association because cancer stem cells are involved 
in generating tumors and progression to metastasis (21, 144-146).  Because of this, the 
role of p53 in differentiation may provide an equal impact on tumor progression as its 
role in DNA damage response.  Therefore, the ability of JNK2 to inhibit luminal cell 
differentiation in spite of the p53/Notch1 interaction not having an effect is an important 
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discovery.  This means that JNK2 regulates luminal differentiation of mammary tumors 
independent of Notch signaling.  
Contrary to the MT tumor model, the p53ko transplant model showed no 
difference in tumorigenesis between jnk2ko and jnk2wt groups.  Differences in 
tumorigenesis in the MT model were attributed to the function of JNK2 in suppression of 
replicative stress (3).  Because this role requires p53 (133), its absence may have 
neutralized differences.  Alternatively, increased Brca1 expression in p53ko;jnk2ko 
tumors may have alleviated stress by potentiating DNA damage response.  
It is interesting to note that the p53ko mutation in these tumors exposed the ability 
of JNK2 to regulate Brca1 expression.  It is not surprising, however, that Brca1 
expression is affected in the p53ko model, as p53 is a known inhibitor of 
Brca1transcription (147).  Because BRCA1 is an important protein for the differentiation 
of normal mammary glands and tumors, it is a strong candidate to potentiate luminal 
differentiation in the absence of Jnk2 expression.  
Induction of EMT is a key process in tumorigenesis and metastasis.  Cells that 
have undergone an EMT are more motile because of decreased cell-cell interactions and 
increased expression of extracellular matrix degrading enzymes.  JNK inhibition has been 
shown to prevent AP-1-dependent polarization and tight junction assembly in 3-
dimensional cultures of mammary epithelial cells, indicative of the role of JNKs in EMT 
(148). Our studies highlight specific proteins involved in this process, such as Vimentin, 
Zeb1, Snail, and others.  Other tumor models have shown that inhibition of JNK2 by 
siRNA causes upregulation of claudins 4, 7, and 9 that are critical for the definition of 
 55 
claudin-low tumors (53, 149).  Because these are important genes for breast tumor 
subtype, they merit further study.   
The fact that EMT is not affected in the MT model, with wildtype p53 expression 
may be due to the p53-dependent brca1 suppression.  Using the p53ko tumor model 
effectively unmasked the downregulation of JNK2 thus revealing a secondary mode of 
luminal cell suppression that it regulates.  Our data did not show a direct mechanism for 
positive regulation of EMT by JNK2, but the ability of brca1 expression to suppress 
EMT accompanied with the ability of JNK2 to suppress brca1 offers a clue.  The large 
array of protein targets that are affected by JNK2 expression may be a result of either its 
interaction with brca1—alternatively, potential interactions with miRNAs such as mir200 
or miRNA pathways may have a similar effect.  
Level of differentiation and expression of ER is of paramount importance in 
prognosis of breast cancer patients.  While poorly differentiated, claudin-low human 
tumors are known for their high expression of EMT, stem cell related genes and poor 
patient prognosis, those tumors expressing ER provide comparatively better outcomes 
(41).  The finding that these two phenotypes are anti-correlative demonstrates their 
relevance in tumor classification.  Additionally, the preceding results establish JNK2 to 
be a critical mediator between EMT and differentiation within Trp53 null tumors.  Recent 
reports that JNK signaling is inactivated at high frequency in human luminal, ER
+
 tumors 
lend support to our data (1, 2), although a significant frequency of mutations Jnk2 was 
not noted.  This may be because higher complexity within the heterogeneous human 
model or that not enough tumors were included in studies to reach statistical significance.  
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Our results have higher resolution in this regard because use of specific Jnk2ko cell lines 
allowed less heterogeneity to observe direct JNKs effects. 
Our results suggest that BRCA1 controls ER
+
 CD24
+
 populations in the p53ko 
model.  BRCA1 is able to sufficiently suppress CD24
-
 tumor initiating cell populations 
and, presumably, its absence promotes them through upregulation of EMT.  The control 
of this interaction by JNK2 is novel; as is its control over vital ER target genes including 
Gata-3 and Pr.  The functional significance of this interaction was found that JNK2 
significantly reduces ER-dependent growth.  Others have shown that high JNK activity 
correlates with tamoxifen resistance in human breast tumors and this provides a potential 
mechanism (150, 151).  Further study could show BRCA1 to be a key target for re-
initiating endocrine therapy sensitization, as well. 
The integral role of BRCA1 in differentiation of luminal cells is well known in 
both normal and tumor contexts but the demonstration that EMT and BRCA1 antagonize 
each other is of particular interest.  This is because of BRCA1’s established role in DNA 
damage response.  This means that undifferentiated cells within mammary tumors may 
have a higher propensity toward double strand DNA breaks and greater chance of 
acquiring mutations to evolve toward metastasis.  This serves to show that differentiation 
may have greater importance than simply changing motile characteristics and growth 
factor receptor expression, but also in slowing cancer progression. 
The overall effect of the BRCA1/EMT interaction is not entirely clarified by 
tumor initiating cell experiments.  Because both CD24
+
 and CD24
-
 populations were 
injected, it is uncertain if increases in tumor initiating capacity is a consequence of 
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intrinsic capacity for the CD24
-
 population to seed tumors and metastasize or if CD24
-
 
populations promote tumor seeding and metastasis of CD24
+
 populations.  In the setting 
of the tumor, EMT not only affects tumor populations, but the tumor microenvironment 
and allows for remodeling by stromal cells.  The potential exists that CD24
-
 populations 
are responsible for remodeling and are not the tumor initiating/metastasizing cells 
themselves.  This question merits further examination.  
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Chapter 6 – Summary and Future Directions 
 
 
 
This project has demonstrated that JNK2 is involved in the suppression of luminal 
populations in both normal mammary and tumor contexts.  Regulation of this process 
involves mechanisms that are both dependent on and independent of Trp53 expression.  
In the p53-dependent mode of luminal cell differentiation, JNK2 inhibits the ability of 
EGF signaling to induce expression of p53 and, subsequently, Notch1 expression.  
Notch1 is well-known to promote luminal populations, and 3-dimensional culture models 
in this report show that elevated Notch signaling is responsible for increased luminal 
populations in jnk2ko mammary epithelial cell preparations.  In the p53-independent 
mode of luminal cell differentiation, JNK2 inhibits luminal differentiation through 
induction of EMT and suppression of luminal differentiation mediators.  BRCA1 is 
downregulated by JNK2 and is sufficient to suppress JNK2-dependent EMT.  This is a 
potential feedback mechanism, as Slug represses Brca1mRNA expression in response to 
Wnt signaling (152).   The particular levels of the stem cell hierarchy that are altered to 
lead to inhibition of luminal populations in our model have not yet been elucidated but 
may be found through higher resolution methods such as those mentioned below. 
In p53-competent normal mammary glands, the manifestation of jnk2ko on 
lineage commitment is increased proportions of Cytokeratin 8/18
+
 and ER
+
 luminal cell 
populations.  This is accompanied by decreased expression of the basal marker, Trp63.  
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Assessment of these markers in whole glands does not give information of the level in the 
hierarchy that is affected by jnk2ko as both Cytokeratin 8/18 and p63 are lineage 
restricted markers but may be expressed by progenitors or mature, differentiated cells.  
The fact that the proportion of ER
+
 cells changes does not indicate a change at any 
specific point in the hierarchy, either, because these cells are highly differentiated and 
only a result of changes occurred earlier in the hierarchy.  It is likely that JNK2 affects 
the hierarchy at multiple levels because notch1 is important for the differentiation of stem 
cells and commitment to the luminal lineage.  Differentiation assays performed on 
putative mammary stem cell- and progenitor-enriched populations support that JNK2 
may inhibit luminal cell commitment and differentiation at both the stem and progenitor 
levels, but results are inconclusive because stem fractions were not validated and further 
assessment of progenitor populations is required.   
Roles for p53 and Notch1 in the promotion of stem cell differentiation are well-
known, thus it is likely that high expression of these proteins in jnk2ko cells will increase 
the propensity for stem populations to differentiate (21, 26, 153).   In contrast, if JNK2 is 
not expressed in mammary stem cells, then levels of Trp53 and Notch1 mRNA would 
remain unaltered and stem cell populations would not be affected as a result.  Histology 
shows that JNK2 is expressed by both the luminal and basal lineages, thus the basally 
located stem cells might also express JNK2.  If this is true, decreased mammary 
repopulating potential and self-renewal capacity are likely consequences of jnk2ko.   
Whether notch1 is dispensable for this response due to p53-dependent downregulation of 
EMT would be interesting to assess.  Mammary repopulating potential could be tested 
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through limiting dilution mammary epithelial cell transplantation experiment using cells 
isolated from jnk2wt and jnk2ko glands.   Additionally, real time in vitro assessment of 
self-renewal would give a higher resolution picture of the effect of JNK2 on stem cell 
commitment and determine if potential effects are due to this stem-related process (21).   
JNK2 may also affect stem cell maintenance independent of its role in 
suppression of Trp53 and Notch1 transcription.  It is unclear, from experiments, if JNK2 
directly promotes EMT independent of BRCA1 or if Brca1 downregulation by JNK2 is 
the direct mechanism of EMT promotion.  If a direct interaction leads to EMT, then 
JNK2 would likely have a role in the promotion of normal mammary stem cell 
populations in the absence of p53 expression.  If the interaction requires downregulation 
of Brca1 mRNA expression, jnk2ko may not have any effect due to luminal lineage-
restricted expression of Brca1 (32, 33, 154).  In this case, BRCA1 expression could not 
be induced in stem cell populations and EMT would not be inhibited.  However, jnk2ko 
may promote ectopic BRCA1 expression and, in turn, promote differentiation.  This 
requires further clarification in normal mammary models.  A mammary specific, 
inducible shBrca1 would be useful in determining the role of brca1 in this process. 
A role for JNK2 in lineage commitment is supported by evidence provided in this 
report—both Notch1 and BRCA1 are critical for the appropriate lineage proportions in 
the mammary gland.  The fact that high expression of Notch1
ICD
 leads to a build-up of 
luminal progenitors (24, 25, 27), whereas the same phenotype is seen in mutants lacking 
expression of BRCA1 (33, 155) illustrates that these genes function  at different stages of 
differentiation in the mammary cell hierarchy—because Notch1 is responsible for effects 
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in earlier progenitors than BRCA1, luminal lineage inhibition by JNK2 could produce 
varied results in overall differentiation of the normal mammary gland depending upon 
p53 status (156).  In p53-competent mice, JNK2-dependent inhibition of Notch1 
expression suppresses mammary luminal cell proportions.  The precise cellular 
mechanism of notch1 in this context is not known.  Presumably, Notch1 mRNA 
expression increases luminal cell proportions by promoting luminal lineage commitment 
or expansion of luminal progenitors but it could also promote opposing effects in the 
basal lineage.  To assess progenitor expansion, differentiation assays could be performed 
using jnk2wt and jnk2ko cells.  The key to this experiment is to examine the size of 
colonies produced—smaller/larger colonies resulting from each lineage-restricted 
progenitor type would indicate a change in progenitor expansion.  It is expected that 
progenitor expansion is the step that is affected by Notch1, as Notch1
ICD
 overexpressing 
mice exhibit hyperproliferation of luminal progenitor cells.  Thus, a similar, but blunted, 
phenotype is expected in differentiation assays of jnk2ko cells.  If this is not the case, then 
lineage commitment must be the step that JNK2 mediates.  Of note, while several 
markers have been defined to evaluate the various steps of luminal cell differentiation, 
essentially no markers, aside from p63, have been published that allow elucidation of 
basal/myoepithelial cell differentiation steps.  Therefore, a role for JNK2 in the 
promotion of basal cell differentiation could be an important observation. 
  In the absence of p53 expression, jnk2ko may cause a decrease in luminal cell 
proportions.  This is because BRCA1 promotes terminal differentiation of luminal 
mammary cells in the normal mammary gland—contrary to its role in the more plastic 
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environment of a tumor where cells continue to proliferate in the face of differentiation.  
The expected normal mammary phenotype is also different from the p53-competent 
phenotype because Notch1 affects progenitor populations and does not promote terminal 
differentiation.  This could be assessed by comparing non-tumor-bearing p53ko;jnk2wt 
and p53ko;jnk2ko mature mammary ducts.  Results that are found from this approach 
could be mechanistically evaluated with differentiation assays to find the specific cause 
of increases/decreases in luminal cell proportions as with Notch1 experiments.  To assess 
the importance of BRCA1 in this model, p53ko;jnk2ko could be combined with 
conditional brca1ko.    
Increased proliferation is also an effect of jnk2ko in the p53ko cells and tumors.  
In normal cell populations, high levels of differentiation are often associated with slowed 
or stalled proliferation.  This does not necessarily hold true in mammary tumors. 
Relatively highly differentiated subtype tumors (Luminal B) are highly proliferative, 
whereas the least differentiated tumors (high EMT) are more slowly proliferating.  
Therefore, use of differentiation as a means of therapy could pose a potential conundrum.  
Undifferentiated tumors are slowly proliferating but invasive and may harbor metastatic 
cancer stem cells but more differentiated tumors are comparatively highly proliferative 
that may quickly progress toward metastasis.  The true measure of benefit, however, is 
patient outcome and targeted therapies with demonstrable efficacy exist for the more 
differentiated tumors such as Luminal A and HER2
+
 while no such therapies exist for 
their undifferentiated counterparts.   
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The importance of differentiation for treatment efficacy is well-illustrated when 
comparing the p53ko;jnk2ko GFP and GFP-JNK2 cell lines.  GFP-JNK2 expression 
induces EMT and dedifferentiation as evidenced by downregulation of ER and PR.  This 
also causes a reduction in responsiveness to the ER inhibitor fulvestrant.  If this 
mechanism exists in human systems, it could provide great benefit to patients whose 
tumors are either unresponsive (Luminal B) or potentially have become resistant to 
endocrine therapies.  Evidence to support these effects are in recent reports that point to a 
potential role for the JNK pathway in suppression of luminal differentiation (1, 2).  
However, in order to fully establish JNKs, or JNK2 in particular, as important in this 
process, human cell lines or primary cells must be manipulated to explore alterations in 
differentiation and/or EMT characteristics.   
As with the costs and benefits that must be weighed with pharmacologically 
inducing differentiation of tumor cells, the potential draw-backs of JNK2 inhibition must 
be considered.  We have found that loss of JNK2 in the MT model is associated with 
increased susceptibility to replicative stress, increased tumor multiplicity, and increased 
tumor latency (3).  This was reinforced by studies of oncogene induced tumorigenesis in 
map2k7 (MKK7)-null mice and jnk2ko in combination with p53+/- (5, 133).  In the p53 
study, Trp53-null mice were also examined and there was no effect on tumor latency with 
jnk2ko, but latency was greatly decreased in p53+/-;jnk2ko mice. This result is 
particularly interesting given that jnk2ko in the absence of p53 causes increased 
Brca1mRNA expression.  Because this may cause increased DNA damage response in 
the face of p53 loss, mutation frequency may be decreased in p53ko;jnk2ko tumors as 
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compared to jnk2wt counterparts.  Therefore, although JNK2 inhibition in tumors 
expressing wildtype p53 may cause a reduction in DNA damage response and increase in 
mutation frequency, it could be potentially beneficial in basal tumors where a high 
frequency of p53 mutation is seen.  The benefit of differentiation and potential ER 
responsiveness when JNK2 expression is absent cannot be overlooked, either. 
These results suggest that JNK2 expression could be used as a predictive marker 
of luminal differentiation and as a potentially important prognostic marker for ER 
responsiveness.  If insights gained using mouse models and various cell lines hold true 
for human models, JNK2 may also be an attractive target for differentiation therapy in 
undifferentiated tumors or tumors that are resistant to endocrine therapies.  There are 
several competitive JNK inhibitors that are commercially available (157-159), although 
the most widely used inhibitor, SP600125, has known cross-reactivity with other MAPKs 
(160).  Newer inhibitors show higher specificity toward JNKs.  One JNK inhibitor by 
Celgene is in clinical trials for treatment of autoimmunity associated with pulmonary 
fibrosis and discoid lupus, but this compound inhibits all JNK proteins and may not have 
a similar effect to jnk2ko when administered.  A more recent approach is development of 
compounds the covalently bind to JNKs with much improved specificity over previous 
drugs (161).  These should be developed and implemented to assess their efficacy and 
this approach will hopefully, one day, lead to increased survival of breast cancer patients 
everywhere.  
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Appendix A – Tables 
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1.1.  Mammary Epithelial Cell Lineage Markers 
 
 
 
 
 
 
 
*while all mammary epithelial cells express CD24, CD29, and CD49f, luminal cells express the highest levels of CD24 and 
basal cells express the highest levels of CD29 and CD49f. 
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3.1.  Colony Forming Assay – Mammary Repopulating Units 
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3.2.  Colony Forming Assay – Colony Forming Units 
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5.1.  Limiting Dilution Assay – Palpable Tumors 
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5.2.  Limiting Dilution Assay – Non-palpable Tumors 
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5.3.  Limiting Dilution Assay – Tumor Initiating Cell Proportions 
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Appendix B – Figures 
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1.1.  Human vs Mouse Mammary Gland Structure 
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1.2.  Mouse Mammary Gland Locations 
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1.3.  Mammary Ductal Structure 
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1.4.  Simplified Mammary Hierarchy 
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3.1.  JNK2 Promotes p63
+
 Myoepithelial Cell Populations 
 
 
 
 
 
 
Mammary glands from seven week-old virgin, adult, female mice were harvested, fixed, 
and embedded in paraffin.  Slides were prepared from these blocks and immunostained to 
analyze p63-positive myoepithelial cell populations.  Significance between groups was 
determined by T-test.  Results are indicated on the figure as follows:  * for  .  ≥p≥ . 1, 
** for  . 1>p≥ .   1, *** for p< .   1.
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3.2.  JNK2 Inhibits Cytokeratin 8/18
+
 Luminal Cell Populations 
 
 
 
 
 
 
 
A:  Mammary glands from seven week-old virgin, adult, female mice were harvested, 
fixed, and embedded in paraffin.  Slides were prepared from these blocks and 
immunostained to analyze Cytokeratin 8/18 (CK8/18)-positive luminal cell populations.  
B:  Isolated mammary epithelial cells were lysed and protein lysates were analyzed for 
CK8/18 expression by western blot.  Significance between groups was determined by T-
test.  Results are indicated on the figure as follows:  * for  .  ≥p≥ . 1, ** for 
 . 1>p≥ .   1, *** for p<0.0001.  No significant difference was found for CK8/18 
expression. 
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3.3.  JNK2 Inhibits ER
+
 Luminal Cell Populations 
 
 
 
 
 
 
Mammary glands from seven week-old virgin, adult, female mice were harvested, fixed, 
and embedded in paraffin.  Slides were prepared from these blocks and immunostained to 
analyze estrogen receptor (ER)-positive luminal cell populations.  Significance between 
groups was determined by T-test.  Results are indicated on the figure as follows:  * for 
 .  ≥p≥ . 1, ** for  . 1>p≥0.0001, *** for p<0.0001. 
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3.4.   JNK2 Inhibits CD24
hi
 CD49f
lo
 Luminal Cell Populations 
 
 
 
 
 
 
 
Mammary glands were harvested from adult virgin, female mice and mammary epithelial 
cells were isolated.  Cells were incubated with CD24 and CD49f antibodies and then 
examined by flow cytometry to evaluate proportions of basal/myoepithelial (CD24
+
 
CD49f
hi
) and luminal (CD24
hi
 CD49f
lo
) cell populations.
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3.5.  JNK2 is Expressed in the Mammary Gland 
 
 
 
 
 
 
 
 
 
 
 
Mammary glands from seven week-old virgin, adult, female mice were harvested, fixed, 
and embedded in paraffin.  Slides were prepared from these blocks and immunostained to 
analyze the localization of JNK2 expression. 
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3.6.  JNK2 Alters Mammary Cell Differentiation in vitro 
 
 
 
 
 
 
 
 
 
 
Mammary glands were harvested from adult virgin, female mice and mammary epithelial 
cells were isolated.  Cells were then seeded onto beds of Matrigel in defined media and 
allowed to grow and differentiate prior to fixation and immunostaining with smooth 
muscle actin (SMA) or Cytokeratin 8/18 (CK8/18) antibodies to recognize differentiated 
basal/myoepithelial and luminal cell populations, respectively 
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3.7.  JNK2 Inhibits Notch-dependent Myoepithelial Cell Suppression 
 
 
Mammary glands were harvested from adult virgin, female mice and mammary epithelial cells were isolated.  Cells were then 
seeded onto beds of Matrigel in defined media with either gamma secretase inhibitor (GSI) or vehicle control (DMSO) and 
allowed to grow and differentiate.  The resulting 3-dimensional structures were immunostained to analyze p63 positive 
basal/myoepithelial cell populations.  2way ANOVA with Bonferroni Post-test was performed and significant values are 
indicated by unique letters.  Ex:  a is significantly different (p<0.05) from b.  
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3.8.  JNK2 Inhibits Notch-dependent Luminal Cell Differentiation 
 
 
Mammary glands were harvested from adult virgin, female mice and mammary epithelial cells were isolated.  Cells were then 
seeded onto beds of Matrigel in defined media with either gamma secretase inhibitor (GSI) or vehicle control (DMSO) and 
allowed to grow and differentiate.  The resulting 3-dimensional structures were immunostained to analyze Cytokeratin 8/18 
(CK 8/18) positive luminal cell populations. 2way ANOVA with Bonferroni Post-test was performed and significant values are 
indicated by unique letters.  Ex:  a is significantly different (p<0.05) from b. 
 85 
3.9.  JNK2 inhibits Notch-dependent Mammary Cell Growth 
 
 
 
Mammary glands were harvested from adult virgin, female mice and mammary epithelial cells were isolated.  Cells were then 
infected with Adenoviruses encoding GFP (AdGFP) or a dominant negative Mastermind-like construct.  Cells were then 
seeded onto beds of Matrigel in defined media and allowed to grow and differentiate.  The resulting 3-dimensional structures 
were either harvested for RNA isolation and hes1 qPCR (A) or photographed for diameter measurement (B).  2way ANOVA 
with Bonferroni Post-test was performed and significant differences (p<0.05) are indicated between columns with different 
letters. 
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3.10.  JNK2 inhibits Notch-dependent Luminal Cell Differentiation 
 
 
 
 
Mammary glands were harvested from adult virgin, female mice and mammary epithelial cells were isolated.  Cells were then 
infected with Adenoviruses encoding GFP (AdGFP) or a dominant negative Mastermind-like construct.  Cells were then 
seeded onto beds of Matrigel in defined media and allowed to grow and differentiate.  The resulting 3-dimensional structures 
were fixed and then luminal populations were assessed by immunofluorescence using an anti-Cytokeratin 8/18 (cyt8/18) 
antibody.  2way ANOVA with Bonferroni Post-test was performed and significant differences (p<0.05) are indicated between 
columns with different letters.
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3.11.  JNK2 Inhibits Notch-dependent Mammary Cell Growth 
 
 
 
 
 
 
Mammary glands were harvested from adult virgin, female mice and mammary epithelial 
cells were isolated.  Cells were then seeded onto beds of Matrigel in defined media with 
either gamma secretase inhibitor (GSI) or vehicle control (DMSO) and allowed to grow 
and differentiate.  The resulting 3-dimensional structures were measured using images 
taken with light microscopy.  2way ANOVA with Bonferroni Post-test was performed 
and significant differences (p<0.05) are indicated between columns with different letters.
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3.12.  JNK2 Does Not Affect Notch Activity in Differentiated Mammary Ducts 
 
 
Mammary glands were harvested from virgin female mice at pubertal time points, then fixed and embedded in paraffin for 
sectioning.  Slides were prepared and immunohistochemistry performed to examine Notch1
ICD
 expression in mammary ducts. 
2way ANOVA with Bonferroni Post-test was performed and no significant differences (p<0.05) were found.  
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3.13.  JNK2 Inhibits Notch Activity in Adult Mammary Terminal End Buds 
 
 
 
Mammary glands were harvested from virgin female mice at pubertal time points, then fixed and embedded in paraffin for 
sectioning.  Slides were prepared and immunohistochemistry performed to examine Notch1
ICD
 expression in terminal end 
buds.  2way ANOVA with Bonferroni Post-test was performed and significant differences (p<0.05) are indicated between 
columns with different letters.
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3.14.  JNK2 Inhibits Expression  and Activity of Notch1 in Mammary Cells 
 
 
 
 
 
 
Mammary glands were harvested from virgin mice and treated with collagenase to 
dissociate adipocytes from mammary epithelium.  Resulting mammary organoids were 
lysed with either Trizol reagent or protein lysis buffer.  Isolated RNA was analyzed for 
hes1 (A) and notch1 (B) expression.  C:  Expression of full length Notch1 protein was 
assessed by western blot. Significance between groups was determined by T-test.  Results 
are indicated on the figure as follows:  * for  .  ≥p≥ . 1, ** for  . 1>p≥ .   1, *** for 
p<0.0001.  
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4.1.  JNK2 Promotes p63
+
 Basal Populations in MT Tumors  
 
 
 
 
 
Tumors from MT+ jnk2wt and jnk2ko mice were previously generated and harvested for 
histology (3).  Sections were cut from these tumor blocks and immunostained to examine 
p63
+
 basal populations. Significance between groups was determined by T-test.  Results 
are indicated on the figure as follows:  * for  .  ≥p≥ . 1, ** for  . 1>p≥ .   1, *** for 
p<0.0001. 
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4.2.  JNK2 Inhibits Cytokeratin 8/18
+
 Luminal Populations in MT Tumors 
 
 
 
 
 
Sections of MT tumors were immunostained to examine Cytokeratin8/18
+
 (Cyt 8/18) 
luminal populations.  Significance between groups was determined by T-test.  Results are 
indicated on the figure as follows:  * for  .  ≥p≥ . 1, ** for  . 1>p≥ .   1, *** for 
p<0.0001. 
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4.3.  JNK2 Inhibits Notch1 Activity in MT Tumors 
 
 
 
 
 
 
 
 
Sections of MT tumors were cut and immunostained to examine Notch1
ICD
 expression. 
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4.4.  JNK2 Inhibits Expression of Notch1 in MT Tumors 
 
 
 
 
 
 
 
 
RNA from MT+ jnk2wt and jnk2ko tumors was previously isolated (3).  Expression of 
notch1 was analyzed by qPCR using these samples.  Significance between groups was 
determined by T-test.  Results are indicated on the figure as follows:  * for  .  ≥p≥ . 1, 
** for  . 1>p≥ .   1, *** for p< .   1 
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4.5.  JNK2 Suppresses Notch Signaling in MT Cells 
 
 
 
Cell lines were previously established from a MT+ jnk2ko tumor and infected with 
viruses encoding either GFP or GFP-JNK2 (3).  These cells were lysed with either Trizol 
reagent or protein lysis buffer.  Isolated RNA was analyzed for notch1 (A) and hes1 (B) 
expression.  C:  Expression of full length Notch1 protein was assessed by western blot.  
Significance between groups was determined by T-test.  Results are indicated on the 
figure as follows:  * for  .  ≥p≥ . 1, ** for  . 1>p≥ .   1, *** for p< .   1.  
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4.6.  JNK2 Inhibits Expression of Trp53 mRNA 
 
 
 
 
 
 
 
 
 
 
 
A:  RNA was isolated from MT cells and expression of p53 was assessed by RT-PCR.  B:  
RNA was isolated from mammary organoids and expression of p53 was assessed by 
qPCR.  Significance between groups was determined by T-test.  Results are indicated on 
the figure as follows:  * for  .  ≥p≥ . 1, ** for  . 1>p≥ .   1, *** for p< .   1 
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4.7.  JNK2 Inhibits EGF-dependent Transcription of Notch1 and Trp53 
 
 
 
MT cells were placed in serum-free media (SFM) to deplete growth factors.  Media was 
then replaced with fresh SFM or SFM supplemented with EGF.  Cells were harvested for 
RNA isolation and expression levels of cyclin-d1 (A), notch1 (B), and p53 (C) were 
examined by qPCR.  2way ANOVA with Bonferroni Post-test was performed and 
significant differences (p<0.05) are indicated between columns with different letters. 
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4.8.  JNK2 Suppresses EGF-dependent Notch1 Promoter Activity 
 
 
 
 
MT cells were transfected with plasmids containing either a wildtype notch1 promoter (N1PR), a notch1 promoter with 
mutated p53 response elements (N1PRp53mut) , or no promoter (N1PRless) attached to luciferase.  Cells were incubated in 
full media (A) or SFM vs EGF (B) and then harvested for luciferase assay.  2way ANOVA with Bonferroni Post-test was 
performed and significant differences (p<0.05) are indicated between columns with different letters.
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4.9.  JNK2 Decreases p53 Binding to the Notch1 Promoter 
 
 
 
 
 
 
 
 
 
MT cells were fixed in formaldehyde and lysed to release chromatin.  Chromatin was 
then sonicated and immunoprecipitated with p53 or IgG as negative control.  Resultant 
DNAs were then amplified by PCR with specific primers surrounding p53 response 
elements within the promoters of p21 (positive control) or notch1.  Glyceraldehyde 3-
Phosphate Dehydrogenase (gapdh) promoter was amplified as a negative control.   
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5.1.  JNK2 Does Not Affect Tumor Latency in Trp53-null Tumors 
 
 
 
 
 
 
 
 
 
 
Mammary glands from p53ko;jnk2wt or p53ko;jnk2ko female mice were transplanted into 
cleared fat pads of 3 week-old female mice.  Growth of mammary tissue was potentiated 
by pituitary isograft.  Time from transplant to tumor palpation is shown.  Logrank test 
showed no significant differences among groups. 
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5.2.  JNK2 Inhibits Growth and Proliferation of Trp53-null Tumors 
 
 
A:  Transplant tumors were measured and harvested at 1.5 cm
2
.  Time from tumor 
palpation to harvest at target size is shown in the Kaplan Meier chart.  Logrank shows 
significant difference in tumor growth (p<0.05) B:  Harvested tumors were divided into 
pieces with parts of each being fixed for histology.  Tumor sections were stained with 
Ki67, a marker of proliferation, and then quantified.  C:  RNA from tumors was used for 
microarray analysis and expression of a proliferation signature was compared between 
p53ko;jnk2wt and p53ko;jnk2ko tumors.  Significance between groups was determined by 
T-test.  Results are indicated on the figure as follows:  * for  .  ≥p≥ . 1, ** for 
 . 1>p≥ .   1, *** for p<0.0001. 
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5.3.  JNK2 Does Not Inhibit Notch1 in the Absence of p53 
 
 
 
A:  Expression of Notch1 was assessed in p53ko transplant tumors.  Significance between groups was determined by T-test.  
Results are indicated on the figure as follows:  * for  .  ≥p≥ . 1, ** for  . 1>p≥ .   1, *** for p< .   1.  B:  A 
p53ko;jnk2ko tumor cell line was generated and infected with viruses carrying either a GFP or GFP-JNK2 transgene.  These 
cells were transfected with notch1 promoter luciferase constructs and assessed for notch1 promoter activity.  2way ANOVA 
with Bonferroni Post-test was performed and significant differences (p<0.05) are indicated between columns with different 
letters. 
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5.4.  JNK2 Inhibits Luminal Marker Expression in Trp53-null Tumors 
 
 
 
 
 
 
 
 
 
A:  Transplant tumor sections were immunostained for Cytokeratin 8/18 (CK 8/18) 
expression to assess luminal cell populations.  B:  Transplant tumor RNAs were assessed 
for expression of basal genes (Cytokeratin14-ck14 and p63) and the luminal gene, brca1, 
by qPCR.  Significance between groups was determined by T-test.  Results are indicated 
on the figure as follows:  * for  .  ≥p≥ . 1, ** for  . 1>p≥ .   1, *** for p< .   1.
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5.5.  JNK2 Inhibits BRCA1 Pathway Expression in Trp53-Null Tumors 
 
 
 
 
 
 
Expression of genes associated with the BRCA1 pathway were assessed in p53ko transplant tumors using microarray analysis. 
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5.6.  JNK2 Inhibits Luminal Marker Expression in Trp53-null Cells 
 
A:  Tumor cell lines generated from a p53ko; jnk2ko cell line were lysed to examine 
expression of basal markers (ck14 and p63) and the luminal marker, brca1, by qPCR.  
Significance between groups was determined by T-test.  Results are indicated on the 
figure as follows:  * for  .  ≥p≥ . 1, ** for  . 1>p≥ .   1, *** for p< .   1.  B:  
brca1 promoter activity was assessed in p53ko;jnk2ko cell lines. 2way ANOVA with 
Bonferroni Post-test was performed and significant differences (p<0.05) are indicated 
between columns with different letters. 
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5.7.  JNK2 Does Not Affect Brca1 Expression in MT Tumors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MT tumor RNA was amplified by qPCR using primers for Brca1. Significance between 
groups was determined by T-test.  Results are indicated on the figure as follows:  * for 
 .  ≥p≥ . 1, ** for  . 1>p≥ .   1, *** for p< .   1.  No significant difference was 
found.  
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5.8.  Brca1 and EMT are Anti-correlated in Breast Tumors 
 
 
 
 
Human tumors from UNC308 (A) and COMBINED855 (B) as well as our own p53ko 
tumor microarrays (C) were ranked by level of Brca1 expression.  The level of 
expression of a set of genes correlated with epithelial to mesenchymal transition (EMT) 
was then plotted against these data points to reveal correlation.  
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5.9.  JNK2 Promotes Epithelial to Mesenchymal Transition 
 
 
 
 
 
Expression of mesenchymal/stem genes in red (twist1, snai1, zeb1, snai2, and klf4) and 
the epithelial gene, e-cadherin in blue, were assessed by qPCR in p53ko tumors (A) and 
p53ko;jnk2ko tumor cell lines (B).  Significance between groups was determined by T-
test.  Results are indicated on the figure as follows:  * for  .  ≥p≥ . 1, ** for 
 . 1>p≥ .   1, *** for p< .   1. 
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5.10.  Microarray Confirms JNK2 Regulation of EMT 
 
 
 
 
 
Expression of mesenchymal/stem (Klf4, Lef1, Mmp9, Six1,Ttwist1,Ttwist2, Vim, Zeb1, 
and Zeb2), E-cadherin (Cdh1), and the luminal marker, ER (Esr1) in p53ko;jnk2ko cell 
lines were assessed by microarray (A) and confirmed by western blot (B). 
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5.11.  JNK2 Promotes EMT Marker Expression in vitro 
 
 
 
 
 
 
Immunocytochemistry was performed on p53ko;jnk2ko cell lines using e-cadherin (A) or 
vimentin (B) antibodies. 
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5.12.  JNK2 Promotes Focal Growth of Cells in Culture 
 
 
 
 
 
 
 
 
 
 
 
 
 
Light microscopy was used to assess morphology of p53ko;jnk2ko cell lines. 
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5.13.  GFP-JNK2 Promotes CD24
-
 Cell Populations 
 
 
 
 
 
 
 
 
 
 
Flow cytometry was used to analyze CD24 and CD49f expression in p53ko;jnk2ko cell 
lines. 
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5.14.  High Expression of GFP-JNK2 Correlates with CD24 Negativity 
 
 
 
 
 
 
 
Flow cytometry was used to examine the correlation of GFP-JNK2 and CD24 expression 
in p53ko;jnk2ko cell lines.  Cells were gated by GFP intensity (medium or high) and then 
assessed for CD24. 
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5.15.  CD24
-
 Populations are Undifferentiated EMT Cells 
 
 
A:  CD24+ and CD24- populations in p53ko;jnk2ko GFP-JNK2 cells were separated by 
flow cytometry and expression of mesenchymal/stem genes (twist1, snai1, zeb1, snai2, 
and klf4), and markers of differentiation (cyt14, p63, cdh1, and brca1) were assessed by 
qPCR.  B:  gata-3, a marker of luminal cells, was assessed by RT-PCR in these same 
populations.  Significant fold differences as determined by T test from basal expression is 
indicated on figure as follows:  * for  .  ≥p≥ . 1, ** for  . 1>p≥ .   1, *** for 
p<0.0001.  
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5.16.  Brca1 is Sufficient to Suppress CD24
-
 Populations 
 
 
 
 
 
GFP and GFP-JNK2 expressing p53ko;jnk2ko cells were transfected with plasmid 
constructs encoding Zeb1 and Brca1, respectively, and CD24/CD49f populations were 
assessed by flow cytometry. 
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5.17.  JNK2 Does Not Alter EMT in MT Tumors 
 
 
 
RNA from MT tumors was analyzed by qPCR for expression of cdh1 (A), snai1 (B), 
snai2 (C), and klf4 (D).  Significance between groups was determined by T-test.  Results 
are indicated on the figure as follows:  * for  .  ≥p≥ . 1, ** for  . 1>p≥ .   1, *** for 
p<0.0001.  No significant differences were found.  
 117 
5.18.  JNK2 Expression Retards Cell Proliferation 
 
A:  Proliferation rates of p53ko;jnk2ko cell lines were measured using MTT assay.  B:  
Flow cytometry was used to analyze BrdU incorporation of CD24
+
 and CD24
-
 
populaitions in p53ko;jnk2ko GFP-JNK2 cells.  2way ANOVA with Bonferroni Post-test 
was performed and significant differences (p<0.05) are indicated between columns with 
different letters. 
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5.19.  JNK2 Inhibits ER Expression and Sensitivity 
 
 
 
 
 
A:  Expression of ER and PR were assessed in p53ko;jnk2ko cell lines by western blot.  
B:  p53ko;jnk2ko cell lines were incubated in growth factor-free charcoal stripped serum 
(CSS), CSS+ estradiol (E2), or CSS+ E2+ fulvestrant (Fulv/F) and ER expression was 
assessed by western blot.  C:  MTT assay was performed on p53ko;jnk2ko cell lines in 
full serum with or without fulvestrant and growth inhibition was calculated.  2way 
ANOVA with Bonferroni Post-test was performed and significant differences (p<0.05) 
are indicated between columns with different letters. 
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Appendix C – Primers 
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qPCR primers:   
 
hes1 ( ’-CACAGAAAGTCATCAAAGCC and  ’-TGCTTGACAGTCATTTCCAG),  
notch1 ( ’-CTACAGAAGGTTACACAG and  ’-CAGAGGTAGGAGTTGTCACG),  
p53 ( ’-TGAACCGCCGACCTATCCTTA and GGCACAAACACGAACCTCAAA),  
twist1 ( ’-AATTCACAAGAATCAGGGCGTGGG and  ’-
TCTATCAGAATGCAGAGGTGTGGG),  
snai1 ( ’-TCCAAACCCACTCGGATGTGAAGA and  ’-
TTGGTGCTTGTGGAGCAAGGACAT),  
snai2 ( ’-CACATTCGAACCCACACATTGGCT and  ’-
TGTGCCCTCAGGTTTGATCTGTCT),  
zeb1 ( ’-CAGTGTTCCATGTTTAAGAGCA and  ’-GTCTTTCATCCTGGTTTCCG),  
klf4 ( ’-CATTATCAAGAGTCTATGCCA and  ’-CACAGTGGTAAGGTTTCTCG),  
cdh1 ( ’-GCCAAGTACATCCTCTATTCTC and  ’-GCAACGAATCCCTCAAAGAC), 
gapdh ( ’-CGTGGAGTCTACTGGCGTCTTCAC and  ’-
CGGGGATGATGAGCCTTTTGGC), 
brca1 ( ’-CCAAAGAAGTAATGACCGTG and  ’-GCTAACTATCCACTTTCCTCC), 
gata-3 ( ’-ACGAATCCAGCACAGAAGG and  ’-ATGTCCCTGCTCTCCTTG), 
cyt14 ( ’-TCTTCAGCAAGACAGAGGAG and  ’-CTCCAGGTTATTCTCCAGGG), 
p63 (5’-GTTCAATGAGGGACAGATTGC and  ’-GAATTCAGTGCCAACCTGTG). 
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ChIP primers 
 
p21 ( ’-GATTTCCTTTCTATCAGCCC and GTCACAAGATACATACCACCT), 
gapdh ( ’-GCCAAAGACAGAAGCCAGGA and  ’-
CAGGATAGGACTCAGGGAATACAG), 
notch1 ( ’-GTGACCGTGGAACGTCTA  ’-CTGTCCTAGGGCTCCAC) 
  
 122 
Works Cited 
 
1. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al. 
The landscape of cancer genes and mutational processes in breast cancer. Nature. 
2012;486:400-4. 
2. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, et al. Whole-genome 
analysis informs breast cancer response to aromatase inhibition. Nature. 
2012;486:353-60. 
3. Chen P, O'Neal JF, Ebelt ND, Cantrell MA, Mitra S, Nasrazadani A, et al. Jnk2 
effects on tumor development, genetic instability and replicative stress in an 
oncogene-driven mouse mammary tumor model. PloS one. 2010;5:e10443. 
4. Cellurale C, Girnius N, Jiang F, Cavanagh-Kyros J, Lu S, Garlick DS, et al. Role 
of JNK in mammary gland development and breast cancer. Cancer research. 
2012;72:472-81. 
5. Cellurale C, Weston CR, Reilly J, Garlick DS, Jerry DJ, Sluss HK, et al. Role of 
JNK in a Trp53-dependent mouse model of breast cancer. PloS one. 
2010;5:e12469. 
6. Mitra S, Lee JS, Cantrell M, Van den Berg CL. c-Jun N-terminal kinase 2 (JNK2) 
enhances cell migration through epidermal growth factor substrate 8 (EPS8). The 
Journal of biological chemistry. 2011;286:15287-97. 
7. Kaoud TS, Mitra S, Lee S, Taliaferro J, Cantrell M, Linse KD, et al. Development 
of JNK2-selective peptide inhibitors that inhibit breast cancer cell migration. ACS 
chemical biology. 2011;6:658-66. 
8. Nasrazadani A, Van Den Berg CL. c-Jun N-terminal Kinase 2 Regulates Multiple 
Receptor Tyrosine Kinase Pathways in Mouse Mammary Tumor Growth and 
Metastasis. Genes & cancer. 2011;2:31-45. 
9. Smith GH, Medina D. A morphologically distinct candidate for an epithelial stem 
cell in mouse mammary gland. Journal of cell science. 1988;90 ( Pt 1):173-83. 
10. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML, et 
al. Generation of a functional mammary gland from a single stem cell. Nature. 
2006;439:84-8. 
11. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D, et al. 
Purification and unique properties of mammary epithelial stem cells. Nature. 
2006;439:993-7. 
12. Stingl J, Raouf A, Emerman JT, Eaves CJ. Epithelial progenitors in the normal 
human mammary gland. Journal of mammary gland biology and neoplasia. 
2005;10:49-59. 
13. Smalley MJ, Titley J, O'Hare MJ. Clonal characterization of mouse mammary 
luminal epithelial and myoepithelial cells separated by fluorescence-activated cell 
sorting. In vitro cellular & developmental biology Animal. 1998;34:711-21. 
 123 
14. Stingl J, Eaves CJ, Zandieh I, Emerman JT. Characterization of bipotent 
mammary epithelial progenitor cells in normal adult human breast tissue. Breast 
cancer research and treatment. 2001;67:93-109. 
15. Sleeman KE, Kendrick H, Ashworth A, Isacke CM, Smalley MJ. CD24 staining 
of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and 
non-epithelial cells. Breast cancer research : BCR. 2006;8:R7. 
16. Stingl J, Raouf A, Eirew P, Eaves CJ. Deciphering the mammary epithelial cell 
hierarchy. Cell cycle (Georgetown, Tex). 2006;5:1519-22. 
17. Pietersen AM, Evers B, Prasad AA, Tanger E, Cornelissen-Steijger P, Jonkers J, 
et al. Bmi1 regulates stem cells and proliferation and differentiation of committed 
cells in mammary epithelium. Current biology : CB. 2008;18:1094-9. 
18. Yang MH, Hsu DS, Wang HW, Wang HJ, Lan HY, Yang WH, et al. Bmi1 is 
essential in Twist1-induced epithelial-mesenchymal transition. Nature cell 
biology. 2010;12:982-92. 
19. Siemens H, Jackstadt R, Hunten S, Kaller M, Menssen A, Gotz U, et al. miR-34 
and SNAIL form a double-negative feedback loop to regulate epithelial-
mesenchymal transitions. Cell cycle (Georgetown, Tex). 2011;10:4256-71. 
20. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: 
acquisition of malignant and stem cell traits. Nature reviews Cancer. 2009;9:265-
73. 
21. Cicalese A, Bonizzi G, Pasi CE, Faretta M, Ronzoni S, Giulini B, et al. The tumor 
suppressor p53 regulates polarity of self-renewing divisions in mammary stem 
cells. Cell. 2009;138:1083-95. 
22. Chang CJ, Chao CH, Xia W, Yang JY, Xiong Y, Li CW, et al. p53 regulates 
epithelial-mesenchymal transition and stem cell properties through modulating 
miRNAs. Nature cell biology. 2011;13:317-23. 
23. Stingl J. Detection and analysis of mammary gland stem cells. The Journal of 
pathology. 2009;217:229-41. 
24. Buono KD, Robinson GW, Martin C, Shi S, Stanley P, Tanigaki K, et al. The 
canonical Notch/RBP-J signaling pathway controls the balance of cell lineages in 
mammary epithelium during pregnancy. Developmental biology. 2006;293:565-
80. 
25. Bouras T, Pal B, Vaillant F, Harburg G, Asselin-Labat ML, Oakes SR, et al. 
Notch signaling regulates mammary stem cell function and luminal cell-fate 
commitment. Cell stem cell. 2008;3:429-41. 
26. Raouf A, Zhao Y, To K, Stingl J, Delaney A, Barbara M, et al. Transcriptome 
analysis of the normal human mammary cell commitment and differentiation 
process. Cell stem cell. 2008;3:109-18. 
27. Lee CW, Simin K, Liu Q, Plescia J, Guha M, Khan A, et al. A functional Notch-
survivin gene signature in basal breast cancer. Breast cancer research : BCR. 
2008;10:R97. 
 124 
28. Morrison SJ, Perez SE, Qiao Z, Verdi JM, Hicks C, Weinmaster G, et al. 
Transient Notch activation initiates an irreversible switch from neurogenesis to 
gliogenesis by neural crest stem cells. Cell. 2000;101:499-510. 
29. Nguyen BC, Lefort K, Mandinova A, Antonini D, Devgan V, Della Gatta G, et al. 
Cross-regulation between Notch and p63 in keratinocyte commitment to 
differentiation. Genes Dev. 2006;20:1028-42. 
30. Yalcin-Ozuysal O, Fiche M, Guitierrez M, Wagner KU, Raffoul W, Brisken C. 
Antagonistic roles of Notch and p63 in controlling mammary epithelial cell fates. 
Cell death and differentiation. 2010;17:1600-12. 
31. Oakes SR, Naylor MJ, Asselin-Labat ML, Blazek KD, Gardiner-Garden M, 
Hilton HN, et al. The Ets transcription factor Elf5 specifies mammary alveolar 
cell fate. Genes Dev. 2008;22:581-6. 
32. Liu S, Ginestier C, Charafe-Jauffret E, Foco H, Kleer CG, Merajver SD, et al. 
BRCA1 regulates human mammary stem/progenitor cell fate. Proceedings of the 
National Academy of Sciences of the United States of America. 2008;105:1680-5. 
33. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, et al. Aberrant luminal 
progenitors as the candidate target population for basal tumor development in 
BRCA1 mutation carriers. Nature medicine. 2009;15:907-13. 
34. Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z. GATA-3 maintains the 
differentiation of the luminal cell fate in the mammary gland. Cell. 
2006;127:1041-55. 
35. Asselin-Labat ML, Sutherland KD, Barker H, Thomas R, Shackleton M, Forrest 
NC, et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and 
luminal-cell differentiation. Nature cell biology. 2007;9:201-9. 
36. van de Ven S, Smit VT, Dekker TJ, Nortier JW, Kroep JR. Discordances in ER, 
PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer 
treatment reviews. 2011;37:422-30. 
37. Society AC. Breast Cancer Facts & Figures 2011-2012. 2011. 
38. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. 
Molecular portraits of human breast tumours. Nature. 2000;406:747-52. 
39. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene 
expression patterns of breast carcinomas distinguish tumor subclasses with 
clinical implications. Proceedings of the National Academy of Sciences of the 
United States of America. 2001;98:10869-74. 
40. Kao KJ, Chang KM, Hsu HC, Huang AT. Correlation of microarray-based breast 
cancer molecular subtypes and clinical outcomes: implications for treatment 
optimization. BMC cancer. 2011;11:143. 
41. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al. 
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of 
breast cancer. Breast cancer research : BCR. 2010;12:R68. 
42. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, 
HER2 status, and prognosis of patients with luminal B breast cancer. Journal of 
the National Cancer Institute. 2009;101:736-50. 
 125 
43. Tran B, Bedard PL. Luminal-B breast cancer and novel therapeutic targets. Breast 
cancer research : BCR. 2011;13:221. 
44. Proia TA, Keller PJ, Gupta PB, Klebba I, Jones AD, Sedic M, et al. Genetic 
predisposition directs breast cancer phenotype by dictating progenitor cell fate. 
Cell stem cell. 2011;8:149-63. 
45. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic 
markers in triple-negative breast cancer. Cancer. 2007;109:25-32. 
46. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. 
Immunohistochemical and clinical characterization of the basal-like subtype of 
invasive breast carcinoma. Clinical cancer research : an official journal of the 
American Association for Cancer Research. 2004;10:5367-74. 
47. Colomer R, Montero S, Lluch A, Ojeda B, Barnadas A, Casado A, et al. 
Circulating HER2 extracellular domain and resistance to chemotherapy in 
advanced breast cancer. Clin Cancer Res 2000 Jun;6(6):2356-62. 
48. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. 
Humanization of an anti-p185HER2 antibody for human cancer therapy. 
Proceedings of the National Academy of Sciences of the United States of 
America. 1992;89:4285-9. 
49. Tokuda Y, Ohnishi Y, Shimamura K, Iwasawa M, Yoshimura M, Ueyama Y, et 
al. In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody 
against c-erbB-2 product. British journal of cancer. 1996;73:1362-5. 
50. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant 
humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of 
paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer 
xenografts. Cancer research. 1998;58:2825-31. 
51. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, et al. Inhibitory 
effects of combinations of HER-2/neu antibody and chemotherapeutic agents used 
for treatment of human breast cancers. Oncogene. 1999;18:2241-51. 
52. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et 
al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of 
HER2-overexpressing metastatic breast cancer. Journal of clinical oncology : 
official journal of the American Society of Clinical Oncology. 2002;20:719-26. 
53. Herschkowitz JI, Zhao W, Zhang M, Usary J, Murrow G, Edwards D, et al. 
Comparative oncogenomics identifies breast tumors enriched in functional tumor-
initiating cells. Proceedings of the National Academy of Sciences of the United 
States of America. 2012;109:2778-83. 
54. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human 
Breast Cancer: Correlation of Relapse and Survival with Amplification of the 
HER-2/neu Oncogene. Science (New York, NY). 1987;235:177-82. 
55. Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated 
observation of breast tumor subtypes in independent gene expression data sets. 
Proceedings of the National Academy of Sciences. 2003;100:8418-23. 
 126 
56. Arnes JB, Brunet JS, Stefansson I, Begin LR, Wong N, Chappuis PO, et al. 
Placental cadherin and the basal epithelial phenotype of BRCA1-related breast 
cancer. Clinical cancer research : an official journal of the American Association 
for Cancer Research. 2005;11:4003-11. 
57. Foulkes WD, Brunet JS, Stefansson IM, Straume O, Chappuis PO, Begin LR, et 
al. The prognostic implication of the basal-like (cyclin E high/p27 
low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-
related breast cancer. Cancer research. 2004;64:830-5. 
58. Teulière J, Faraldo MM, Deugnier M-A, Shtutman M, Ben-Ze'ev A, Thiery JP, et 
al. Targeted activation of β-catenin signaling in basal mammary epithelial cells 
affects mammary development and leads to hyperplasia. Development 
(Cambridge, England). 2005;132:267-77. 
59. Liu BY, McDermott SP, Khwaja SS, Alexander CM. The transforming activity of 
Wnt effectors correlates with their ability to induce the accumulation of mammary 
progenitor cells. Proceedings of the National Academy of Sciences. 
2004;101:4158-63. 
60. Asselin-Labat ML, Shackleton M, Stingl J, Vaillant F, Forrest NC, Eaves CJ, et 
al. Steroid hormone receptor status of mouse mammary stem cells. Journal of the 
National Cancer Institute. 2006;98:1011-4. 
61. Lan T, Chen Y, Sang J, Wu Y, Wang Y, Jiang L, et al. Type II cGMP-dependent 
protein kinase inhibits EGF-induced MAPK/JNK signal transduction in breast 
cancer cells. Oncology reports. 2012;27:2039-44. 
62. Farias GG, Alfaro IE, Cerpa W, Grabowski CP, Godoy JA, Bonansco C, et al. 
Wnt-5a/JNK signaling promotes the clustering of PSD-95 in hippocampal 
neurons. The Journal of biological chemistry. 2009;284:15857-66. 
63. Killick R, Ribe EM, Al-Shawi R, Malik B, Hooper C, Fernandes C, et al. 
Clusterin regulates beta-amyloid toxicity via Dickkopf-1-driven induction of the 
wnt-PCP-JNK pathway. Molecular psychiatry. 2012. 
64. Qiu W, Chen L, Kassem M. Activation of non-canonical Wnt/JNK pathway by 
Wnt3a is associated with differentiation fate determination of human bone 
marrow stromal (mesenchymal) stem cells. Biochemical and biophysical research 
communications. 2011;413:98-104. 
65. Kesavan K, Lobel-Rice K, Sun W, Lapadat R, Webb S, Johnson GL, et al. 
MEKK2 regulates the coordinate activation of ERK5 and JNK in response to 
FGF-2 in fibroblasts. Journal of cellular physiology. 2004;199:140-8. 
66. Cha Y, Kim DK, Hyun J, Kim SJ, Park KS. TCEA3 binds to TGF-beta receptor I 
and induces Smad-independent, JNK-dependent apoptosis in ovarian cancer cells. 
Cellular signalling. 2013. 
67. Wang W, Zhou G, Hu MC, Yao Z, Tan TH. Activation of the hematopoietic 
progenitor kinase-1 (HPK1)-dependent, stress-activated c-Jun N-terminal kinase 
(JNK) pathway by transforming growth factor beta (TGF-beta)-activated kinase 
(TAK1), a kinase mediator of TGF beta signal transduction. The Journal of 
biological chemistry. 1997;272:22771-5. 
 127 
68. Zhang Y, Neo SY, Wang X, Han J, Lin S-C. Axin Forms a Complex with 
MEKK1 and Activates c-Jun NH2-terminal Kinase/Stress-activated Protein 
Kinase through Domains Distinct from Wnt Signaling. Journal of Biological 
Chemistry. 1999;274:35247-54. 
69. Tang F, Tang G, Xiang J, Dai Q, Rosner MR, Lin A. The absence of NF-kappaB-
mediated inhibition of c-Jun N-terminal kinase activation contributes to tumor 
necrosis factor alpha-induced apoptosis. Molecular and cellular biology. 
2002;22:8571-9. 
70. Nishitoh H, Saitoh M, Mochida Y, Takeda K, Nakano H, Rothe M, et al. ASK1 is 
essential for JNK/SAPK activation by TRAF2. Molecular cell. 1998;2:389-95. 
71. Alter J, Rozentzweig D, Bengal E. Inhibition of myoblast differentiation by tumor 
necrosis factor alpha is mediated by c-Jun N-terminal kinase 1 and leukemia 
inhibitory factor. The Journal of biological chemistry. 2008;283:23224-34. 
72. Van Slambrouck S, Grijelmo C, De Wever O, Bruyneel E, Emami S, Gespach C, 
et al. Activation of the FAK-src molecular scaffolds and p130Cas-JNK signaling 
cascades by alpha1-integrins during colon cancer cell invasion. International 
journal of oncology. 2007;31:1501-8. 
73. Wilson DJ, Fortner KA, Lynch DH, Mattingly RR, Macara IG, Posada JA, et al. 
JNK, but not MAPK, activation is associated with Fas-mediated apoptosis in 
human T cells. European journal of immunology. 1996;26:989-94. 
74. Zanke BW, Boudreau K, Rubie E, Winnett E, Tibbles LA, Zon L, et al. The 
stress-activated protein kinase pathway mediates cell death following injury 
induced by cis-platinum, UV irradiation or heat. Current biology : CB. 
1996;6:606-13. 
75. Robitaille K, Daviau A, Lachance G, Couture JP, Blouin R. Calphostin C-induced 
apoptosis is mediated by a tissue transglutaminase-dependent mechanism 
involving the DLK/JNK signaling pathway. Cell death and differentiation. 
2008;15:1522-31. 
76. Yang DD, Kuan CY, Whitmarsh AJ, Rincon M, Zheng TS, Davis RJ, et al. 
Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking 
the Jnk3 gene. Nature. 1997;389:865-70. 
77. Harkin DP, Bean JM, Miklos D, Song YH, Truong VB, Englert C, et al. Induction 
of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression 
of BRCA1. Cell. 1999;97:575-86. 
78. Xu Z, Maroney AC, Dobrzanski P, Kukekov NV, Greene LA. The MLK family 
mediates c-Jun N-terminal kinase activation in neuronal apoptosis. Molecular and 
cellular biology. 2001;21:4713-24. 
79. Deng Y, Ren X, Yang L, Lin Y, Wu X. A JNK-dependent pathway is required for 
TNFalpha-induced apoptosis. Cell. 2003;115:61-70. 
80. Schreiber M, Kolbus A, Piu F, Szabowski A, Mohle-Steinlein U, Tian J, et al. 
Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev. 
1999;13:607-19. 
 128 
81. Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A, et al. Requirement 
of JNK for stress-induced activation of the cytochrome c-mediated death 
pathway. Science (New York, NY). 2000;288:870-4. 
82. Nuntharatanapong N, Chen K, Sinhaseni P, Keaney JF, Jr. EGF receptor-
dependent JNK activation is involved in arsenite-induced p21Cip1/Waf1 
upregulation and endothelial apoptosis. American journal of physiology Heart and 
circulatory physiology. 2005;289:H99-H107. 
83. Buschmann T, Potapova O, Bar-Shira A, Ivanov VN, Fuchs SY, Henderson S, et 
al. Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for 
p53 stabilization and transcriptional activities in response to stress. Molecular and 
cellular biology. 2001;21:2743-54. 
84. Fuchs SY, Adler V, Pincus MR, Ronai Z. MEKK1/JNK signaling stabilizes and 
activates p53. Proceedings of the National Academy of Sciences of the United 
States of America. 1998;95:10541-6. 
85. Bost F, McKay R, Bost M, Potapova O, Dean NM, Mercola D. The Jun kinase 2 
isoform is preferentially required for epidermal growth factor-induced 
transformation of human A549 lung carcinoma cells. Molecular and cellular 
biology. 1999;19:1938-49. 
86. Potapova O, Gorospe M, Dougherty RH, Dean NM, Gaarde WA, Holbrook NJ. 
Inhibition of c-Jun N-terminal kinase 2 expression suppresses growth and induces 
apoptosis of human tumor cells in a p53-dependent manner. Molecular and 
cellular biology. 2000;20:1713-22. 
87. Chen N, Nomura M, She QB, Ma WY, Bode AM, Wang L, et al. Suppression of 
skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice. Cancer 
research. 2001;61:3908-12. 
88. She QB, Chen N, Bode AM, Flavell RA, Dong Z. Deficiency of c-Jun-NH(2)-
terminal kinase-1 in mice enhances skin tumor development by 12-O-
tetradecanoylphorbol-13-acetate. Cancer research. 2002;62:1343-8. 
89. Kim CG, Lee JJ, Jung DY, Jeon J, Heo HS, Kang HC, et al. Profiling of 
differentially expressed genes in human stem cells by cDNA microarray. 
Molecules and cells. 2006;21:343-55. 
90. Mandal A, Bhowmik S, Patki A, Viswanathan C, Majumdar AS. Derivation, 
characterization, and gene expression profile of two new human ES cell lines 
from India. Stem cell research. 2010;5:173-87. 
91. Brill LM, Xiong W, Lee KB, Ficarro SB, Crain A, Xu Y, et al. Phosphoproteomic 
analysis of human embryonic stem cells. Cell stem cell. 2009;5:204-13. 
92. Ryu JM, Han HJ. L-threonine regulates G1/S phase transition of mouse 
embryonic stem cells via PI3K/Akt, MAPKs, and mTORC pathways. The Journal 
of biological chemistry. 2011;286:23667-78. 
93. Cellurale C, Sabio G, Kennedy NJ, Das M, Barlow M, Sandy P, et al. 
Requirement of c-Jun NH(2)-terminal kinase for Ras-initiated tumor formation. 
Molecular and cellular biology. 2011;31:1565-76. 
 129 
94. Liu Q, Zhang Y, Mao H, Chen W, Luo N, Zhou Q, et al. A crosstalk between the 
Smad and JNK signaling in the TGF-beta-induced epithelial-mesenchymal 
transition in rat peritoneal mesothelial cells. PloS one. 2012;7:e32009. 
95. Matsuda K, Sato A, Okada M, Shibuya K, Seino S, Suzuki K, et al. Targeting 
JNK for therapeutic depletion of stem-like glioblastoma cells. Scientific reports. 
2012;2:516. 
96. Cui J, Han SY, Wang C, Su W, Harshyne L, Holgado-Madruga M, et al. c-Jun 
NH(2)-terminal kinase 2alpha2 promotes the tumorigenicity of human 
glioblastoma cells. Cancer research. 2006;66:10024-31. 
97. Kyriakis JM, Banerjee P, Nikolakaki E, Dai T, Rubie EA, Ahmad MF, et al. The 
stress-activated protein kinase subfamily of c-Jun kinases. Nature. 1994;369:156-
60. 
98. Kallunki T, Deng T, Hibi M, Karin M. c-Jun can recruit JNK to phosphorylate 
dimerization partners via specific docking interactions. Cell. 1996;87:929-39. 
99. Gonzalez FA, Raden DL, Davis RJ. Identification of substrate recognition 
determinants for human ERK1 and ERK2 protein kinases. The Journal of 
biological chemistry. 1991;266:22159-63. 
100. Xie X, Gu Y, Fox T, Coll JT, Fleming MA, Markland W, et al. Crystal structure 
of JNK3: a kinase implicated in neuronal apoptosis. Structure (London, England : 
1993). 1998;6:983-91. 
101. Heo YS, Kim SK, Seo CI, Kim YK, Sung BJ, Lee HS, et al. Structural basis for 
the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125. 
The EMBO journal. 2004;23:2185-95. 
102. Shaw D, Wang SM, Villasenor AG, Tsing S, Walter D, Browner MF, et al. The 
crystal structure of JNK2 reveals conformational flexibility in the MAP kinase 
insert and indicates its involvement in the regulation of catalytic activity. Journal 
of molecular biology. 2008;383:885-93. 
103. Lawler S, Fleming Y, Goedert M, Cohen P. Synergistic activation of 
SAPK1/JNK1 by two MAP kinase kinases in vitro. Current biology : CB. 
1998;8:1387-90. 
104. Kallunki T, Su B, Tsigelny I, Sluss HK, Derijard B, Moore G, et al. JNK2 
contains a specificity-determining region responsible for efficient c-Jun binding 
and phosphorylation. Genes Dev. 1994;8:2996-3007. 
105. Sluss HK, Barrett T, Derijard B, Davis RJ. Signal transduction by tumor necrosis 
factor mediated by JNK protein kinases. Molecular and cellular biology. 
1994;14:8376-84. 
106. Gupta S, Barrett T, Whitmarsh AJ, Cavanagh J, Sluss HK, Derijard B, et al. 
Selective interaction of JNK protein kinase isoforms with transcription factors. 
The EMBO journal. 1996;15:2760-70. 
107. Kuan CY, Whitmarsh AJ, Yang DD, Liao G, Schloemer AJ, Dong C, et al. A 
critical role of neural-specific JNK3 for ischemic apoptosis. Proceedings of the 
National Academy of Sciences of the United States of America. 2003;100:15184-
9. 
 130 
108. Zhan L, Rosenberg A, Bergami KC, Yu M, Xuan Z, Jaffe AB, et al. Deregulation 
of scribble promotes mammary tumorigenesis and reveals a role for cell polarity 
in carcinoma. Cell. 2008;135:865-78. 
109. Society AC. Cancer Treatment and Survivorship Facts & Figures 2012-2013. 
2012. 
110. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, et 
al. Tumor spectrum analysis in p53-mutant mice. Current biology : CB. 1994;4:1-
7. 
111. Kuan CY, Yang DD, Samanta Roy DR, Davis RJ, Rakic P, Flavell RA. The Jnk1 
and Jnk2 protein kinases are required for regional specific apoptosis during early 
brain development. Neuron. 1999;22:667-76. 
112. Lefort K, Mandinova A, Ostano P, Kolev V, Calpini V, Kolfschoten I, et al. 
Notch1 is a p53 target gene involved in human keratinocyte tumor suppression 
through negative regulation of ROCK1/2 and MRCKalpha kinases. Genes Dev. 
2007;21:562-77. 
113. Yugawa T, Handa K, Narisawa-Saito M, Ohno S, Fujita M, Kiyono T. Regulation 
of Notch1 gene expression by p53 in epithelial cells. Molecular and cellular 
biology. 2007;27:3732-42. 
114. DiNardo DN, Butcher DT, Robinson DP, Archer TK, Rodenhiser DI. Functional 
analysis of CpG methylation in the BRCA1 promoter region. Oncogene. 
2001;20:5331-40. 
115. Welm BE, Dijkgraaf GJ, Bledau AS, Welm AL, Werb Z. Lentiviral transduction 
of mammary stem cells for analysis of gene function during development and 
cancer. Cell stem cell. 2008;2:90-102. 
116. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of 
MCF-10A mammary epithelial acini grown in three-dimensional basement 
membrane cultures. Methods (San Diego, Calif). 2003;30:256-68. 
117. Jerry DJ, Kittrell FS, Kuperwasser C, Laucirica R, Dickinson ES, Bonilla PJ, et 
al. A mammary-specific model demonstrates the role of the p53 tumor suppressor 
gene in tumor development. Oncogene. 2000;19:1052-8. 
118. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, et al. 
Identification of conserved gene expression features between murine mammary 
carcinoma models and human breast tumors. Genome biology. 2007;8:R76. 
119. de Hoon MJ, Imoto S, Nolan J, Miyano S. Open source clustering software. 
Bioinformatics (Oxford, England). 2004;20:1453-4. 
120. Saldanha AJ. Java Treeview--extensible visualization of microarray data. 
Bioinformatics (Oxford, England). 2004;20:3246-8. 
121. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the 
activation mechanism. Cell. 2009;137:216-33. 
122. Wu L, Sun T, Kobayashi K, Gao P, Griffin JD. Identification of a family of 
mastermind-like transcriptional coactivators for mammalian notch receptors. 
Molecular and cellular biology. 2002;22:7688-700. 
 131 
123. Hu C, Dievart A, Lupien M, Calvo E, Tremblay G, Jolicoeur P. Overexpression 
of activated murine Notch1 and Notch3 in transgenic mice blocks mammary 
gland development and induces mammary tumors. Am J Pathol. 2006;168:973-
90. 
124. Gallahan D, Jhappan C, Robinson G, Hennighausen L, Sharp R, Kordon E, et al. 
Expression of a truncated Int3 gene in developing secretory mammary epithelium 
specifically retards lobular differentiation resulting in tumorigenesis. Cancer 
research. 1996;56:1775-85. 
125. Mazzone M, Selfors LM, Albeck J, Overholtzer M, Sale S, Carroll DL, et al. 
Dose-dependent induction of distinct phenotypic responses to Notch pathway 
activation in mammary epithelial cells. Proceedings of the National Academy of 
Sciences of the United States of America. 2010;107:5012-7. 
126. Rahman M, Zhang Z, Mody AA, Su DM, Das HK. Intraperitoneal injection of 
JNK-specific inhibitor SP600125 inhibits the expression of presenilin-1 and 
Notch signaling in mouse brain without induction of apoptosis. Brain research. 
2012;1448:117-28. 
127. Tsao PN, Wei SC, Huang MT, Lee MC, Chou HC, Chen CY, et al. 
Lipopolysaccharide-induced Notch signaling activation through JNK-dependent 
pathway regulates inflammatory response. Journal of biomedical science. 
2011;18:56. 
128. Liao YF, Wang BJ, Cheng HT, Kuo LH, Wolfe MS. Tumor necrosis factor-alpha, 
interleukin-1beta, and interferon-gamma stimulate gamma-secretase-mediated 
cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. 
The Journal of biological chemistry. 2004;279:49523-32. 
129. Curry CL, Reed LL, Nickoloff BJ, Miele L, Foreman KE. Notch-independent 
regulation of Hes-1 expression by c-Jun N-terminal kinase signaling in human 
endothelial cells. Laboratory investigation; a journal of technical methods and 
pathology. 2006;86:842-52. 
130. Kim JW, Kim MJ, Kim KJ, Yun HJ, Chae JS, Hwang SG, et al. Notch interferes 
with the scaffold function of JNK-interacting protein 1 to inhibit the JNK 
signaling pathway. Proceedings of the National Academy of Sciences of the 
United States of America. 2005;102:14308-13. 
131. Kolev V, Mandinova A, Guinea-Viniegra J, Hu B, Lefort K, Lambertini C, et al. 
EGFR signalling as a negative regulator of Notch1 gene transcription and 
function in proliferating keratinocytes and cancer. Nature cell biology. 
2008;10:902-11. 
132. Ravitz MJ, Yan S, Dolce C, Kinniburgh AJ, Wenner CE. Differential regulation 
of p27 and cyclin D1 by TGF-beta and EGF in C3H 10T1/2 mouse fibroblasts. 
Journal of cellular physiology. 1996;168:510-20. 
133. Schramek D, Kotsinas A, Meixner A, Wada T, Elling U, Pospisilik JA, et al. The 
stress kinase MKK7 couples oncogenic stress to p53 stability and tumor 
suppression. Nature genetics. 2011;43:212-9. 
 132 
134. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Jr., Butel 
JS, et al. Mice deficient for p53 are developmentally normal but susceptible to 
spontaneous tumours. Nature. 1992;356:215-21. 
135. Tzeng YJ, Zimmermann C, Guhl E, Berg B, Avantaggiati ML, Graessmann A. 
SV40 T/t-antigen induces premature mammary gland involution by apoptosis and 
selects for p53 missense mutation in mammary tumors. Oncogene. 1998;16:2103-
14. 
136. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, et al. A 
comparison of PAM50 intrinsic subtyping with immunohistochemistry and 
clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast 
cancer. Clinical cancer research : an official journal of the American Association 
for Cancer Research. 2010;16:5222-32. 
137. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, et al. Core 
epithelial-to-mesenchymal transition interactome gene-expression signature is 
associated with claudin-low and metaplastic breast cancer subtypes. Proceedings 
of the National Academy of Sciences of the United States of America. 
2010;107:15449-54. 
138. Vieira AF, Ricardo S, Ablett MP, Dionisio MR, Mendes N, Albergaria A, et al. P-
cadherin is coexpressed with CD44 and CD49f and mediates stem cell properties 
in basal-like breast cancer. Stem cells (Dayton, Ohio). 2012;30:854-64. 
139. Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL, et al. 
Progesterone induces adult mammary stem cell expansion. Nature. 2010;465:803-
7. 
140. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The 
epithelial-mesenchymal transition generates cells with properties of stem cells. 
Cell. 2008;133:704-15. 
141. Jiang Z, Deng T, Jones R, Li H, Herschkowitz JI, Liu JC, et al. Rb deletion in 
mouse mammary progenitors induces luminal-B or basal-like/EMT tumor 
subtypes depending on p53 status. The Journal of clinical investigation. 
2010;120:3296-309. 
142. Herschkowitz JI, He X, Fan C, Perou CM. The functional loss of the 
retinoblastoma tumour suppressor is a common event in basal-like and luminal B 
breast carcinomas. Breast cancer research : BCR. 2008;10:R75. 
143. Valentin MD, da Silva SD, Privat M, Alaoui-Jamali M, Bignon YJ. Molecular 
insights on basal-like breast cancer. Breast cancer research and treatment. 
2012;134:21-30. 
144. Liu Y, Elf SE, Miyata Y, Sashida G, Huang G, Di Giandomenico S, et al. p53 
regulates hematopoietic stem cell quiescence. Cell stem cell. 2009;4:37-48. 
145. Armesilla-Diaz A, Bragado P, Del Valle I, Cuevas E, Lazaro I, Martin C, et al. 
p53 regulates the self-renewal and differentiation of neural precursors. 
Neuroscience. 2009;158:1378-89. 
 133 
146. Meletis K, Wirta V, Hede SM, Nister M, Lundeberg J, Frisen J. p53 suppresses 
the self-renewal of adult neural stem cells. Development (Cambridge, England). 
2006;133:363-9. 
147. Arizti P, Fang L, Park I, Yin Y, Solomon E, Ouchi T, et al. Tumor suppressor p53 
is required to modulate BRCA1 expression. Molecular and cellular biology. 
2000;20:7450-9. 
148. Murtagh J, McArdle E, Gilligan E, Thornton L, Furlong F, Martin F. Organization 
of mammary epithelial cells into 3D acinar structures requires glucocorticoid and 
JNK signaling. The Journal of cell biology. 2004;166:133-43. 
149. Carrozzino F, Pugnale P, Feraille E, Montesano R. Inhibition of basal p38 or JNK 
activity enhances epithelial barrier function through differential modulation of 
claudin expression. American journal of physiology Cell physiology. 
2009;297:C775-87. 
150. Johnston SR, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M, et al. Increased 
activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in 
human breast tumors with acquired tamoxifen resistance. Clinical cancer research 
: an official journal of the American Association for Cancer Research. 
1999;5:251-6. 
151. Buse P, Woo PL, Alexander DB, Reza A, Firestone GL. Glucocorticoid-induced 
functional polarity of growth factor responsiveness regulates tight junction 
dynamics in transformed mammary epithelial tumor cells. The Journal of 
biological chemistry. 1995;270:28223-7. 
152. Wu ZQ, Li XY, Hu CY, Ford M, Kleer CG, Weiss SJ. Canonical Wnt signaling 
regulates Slug activity and links epithelial-mesenchymal transition with 
epigenetic Breast Cancer 1, Early Onset (BRCA1) repression. Proceedings of the 
National Academy of Sciences of the United States of America. 2012;109:16654-
9. 
153. Morrison SJ, Kimble J. Asymmetric and symmetric stem-cell divisions in 
development and cancer. Nature. 2006;441:1068-74. 
154. Marquis ST, Rajan JV, Wynshaw-Boris A, Xu J, Yin GY, Abel KJ, et al. The 
developmental pattern of Brca1 expression implies a role in differentiation of the 
breast and other tissues. Nature genetics. 1995;11:17-26. 
155. Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, Natrajan R, et al. 
BRCA1 basal-like breast cancers originate from luminal epithelial progenitors 
and not from basal stem cells. Cell stem cell. 2010;7:403-17. 
156. Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving 
complexities. Cell stem cell. 2012;10:717-28. 
157. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, et al. 
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proceedings 
of the National Academy of Sciences. 2001;98:13681-6. 
158. Carboni S, Hiver A, Szyndralewiez C, Gaillard P, Gotteland J-P, Vitte P-A. 
AS601245 (1,3-Benzothiazol-2-yl (2-{[2-(3-pyridinyl) ethyl] amino}-4 
pyrimidinyl) Acetonitrile): A c-Jun NH2-Terminal Protein Kinase Inhibitor with 
 134 
Neuroprotective Properties. Journal of Pharmacology and Experimental 
Therapeutics. 2004;310:25-32. 
159. Ferrandi C, Ballerio R, Gaillard P, Giachetti C, Carboni S, Vitte P-A, et al. 
Inhibition of c-Jun N-terminal kinase decreases cardiomyocyte apoptosis and 
infarct size after myocardial ischemia and reperfusion in anaesthetized rats. 
British Journal of Pharmacology. 2004;142:953-60. 
160. Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase 
inhibitors: an update. The Biochemical journal. 2003;371:199-204. 
161. Zhang T, Inesta-Vaquera F, Niepel M, Zhang J, Ficarro SB, Machleidt T, et al. 
Discovery of potent and selective covalent inhibitors of JNK. Chemistry & 
biology. 2012;19:140-54. 
 
 135 
Vita 
Michael was born in St. Louis County, Missouri and attended Pattonville Senior High 
School in Maryland Heights before moving on to Omaha, Nebraska to pursue his 
Bachelor of Science degree in Biology at Creighton University. While in Omaha, 
Michael performed biochemical research at Boys’ Town National Research Hospital, 
under the supervision of Dr. Dominic Cosgrove.  Michael received the Phi Sigma 
Outstanding Research Award for this work. Michael graduated in 2006 and began post-
graduate studies in Cellular and Molecular Biology at the University of Texas at Austin 
under the supervision of Dr. Carla L. Van Den Berg.  During his graduate studies, 
Michael received a fellowship from the Institute of Cellular and Molecular Biology as 
well as two nominations for Outstanding Teaching Assistant of the Year from the College 
of Natural Sciences, winning the award once.  
 
 
 
 
 
 
 
This dissertation was typed by the author, Michael Andrew Cantrell. 
Permanent Address: 3087 Post Port Lane 
Maryland Heights, MO 63043 
